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1 Summary 
 
Regulatory T (Treg) cells are generated in the thymus and are involved in the 
regulation of self-tolerance, immune homeostasis and immune responses. So far the 
mechanisms behind the Treg cell differentiation and their function are not fully 
understood. The work of this thesis aimed to gain insight into these processes. We 
used a quantitative differential proteomics approach and identified 164 proteins that 
were differentially expressed in Treg cells compared to conventional T cells. Among 
these transcription factor 7 (TCF7) was identified as a promising candidate for further 
investigations of its role in Treg cells. Using a Tcf7-deficient mouse model we 
observed elevated frequencies of Treg cells among CD4 single-positive and CD4 CD8 
double-positive thymocytes in the absence of TCF7. Quite surprisingly, we also found 
a fraction of CD4 CD8 double-negative cells that expressed the Treg cell transcription 
factor forkhead box P3 (FOXP3) independent of previous T cell receptor 
engagement, indicating that TCF7 prevents premature FOXP3 expression. In vitro 
Treg precursor differentiation assays showed that the reduction of TCF7 levels was 
beneficial for the Treg cell generation capacity and that TCF7 activation through the 
β-catenin/Wnt pathway had the opposite effect. Furthermore, our results indicated 
that FOXP3 supports down regulation of TCF7, as FOXP3 expression in thymocytes 
was accompanied by decreased levels of TCF7 and enforced expression of FOXP3 
in T cells caused reduced expression levels of TCF7. 
In addition to its role in thymic Treg cell differentiation, we found that TCF7 was 
involved in regulating the balance between Treg and TH17 cells and the survival of 
NKT cells. TCF7 deficiency also changed the typical expression patterns of Treg and 
T cell markers.  
In summary, we propose that TCF7 is involved in limiting the access into the Treg cell 
lineage and that TCF7 influences peripheral T cell subsets. 
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2 Zusammenfassung 
 
Regulatorische T (Treg) Zellen entstehen im Thymus und sind beteiligt an der 
Regulierung der Immunantwort, der Selbsttoleranz und der Immunhomöostase im 
Gewebe. Zurzeit sind die Mechanismen der Treg Zellentstehung und ihrer Funktion 
noch nicht vollständig aufgeklärt. Zielsetzung dieser Doktorarbeit war es diese 
Mechanismen weiter zu untersuchen. Mithilfe einer quantitativ differentiellen 
massenspektroskopischen Herangehensweise war es uns möglich 164 Proteine zu 
identifizieren, die in Treg Zellen im Vergleich zu konventionellen T Zellen differentiell 
exprimiert wurden. Zur weiteren Untersuchung seiner Funktion in Treg Zellen wurde 
der Transkriptionsfaktor 7 (TCF7) als ein vielversprechender Kandidat befunden. 
Durch die Verwendung eines Tcf7-defizienten Mausmodells konnten wir beobachten, 
dass die Abwesenheit von TCF7 die Anteile von Treg Zellen unter den CD4 
einzelpositiven und CD4 CD8 doppeltpositiven Zellen erhöhte. Überraschender 
Weise konnten wir auch einen Anteil von CD4 CD8 doppeltnegativen Zellen 
feststellen, die den Treg Zell Transkriptionsfaktor forkhead box P3 (FOXP3) 
unabhängig von vorangegangener T Zell Rezeptor Interaktion exprimierten. Dies 
deutet darauf hin, dass TCF7 die frühzeitige Expression von FOXP3 verhindert. In 
vitro Versuche zur Treg Vorläuferdifferenzierung zeigten, dass sich verringerte TCF7 
Level positiv auf deren Differenzierungspotential auswirkten und dass die Aktivierung 
von TCF7 durch den β-catenin/Wnt Signalweg den gegenteiligen Effekt hatte. 
Darüber hinaus deuteten unsere Ergebnisse darauf hin, dass FOXP3 die 
Herabregulierung von TCF7 unterstützt, da die Expression von FOXP3 in T Zellen 
und Treg Vorläufen zeitgleich mit der verringerter TCF7 Expression auftrat.  
Neben seiner Rolle bei der Differenzierung von Treg Zellen haben wir 
herausgefunden, dass TCF7 an der Regulierung der Balance zwischen Treg und TH17 
Zellen, sowie dem Überleben von NKT Zellen beteiligt war. TCF7 Defizienz 
veränderte außerdem die typischen Expressionsmuster von Treg und T Zell Markern.  
Zusammenfassend implizieren unsere Daten, dass TCF7 an der Limitierung des 
Zugangs zur Treg Zelllinie beteiligt ist und dass TCF7 zusätzlich periphere T 
Zelluntergruppen beeinflusst.  
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3 Introduction 
 
3.1 The immune system 
 
3.1.1 General overview 
 
The mammalian immune system consists of different tissue, cellular and molecular 
components that all work together to protect from disease. Various pathogens like 
viruses, bacteria, fungi or parasites can cause disease and are found in our 
environment. Pathogens greatly differ in their surface structures, their way of 
replication and their mechanisms of pathogenesis. Once the microorganism enters 
the body, the immune system is challenged to recognize, contain and eliminate the 
infection. Besides these environmental threats the immune system is faced with 
autoreactive, damaged or transformed cancerous cells of the host itself. Impaired 
function of the immune system can cause allergies, autoimmune disease or infection 
with opportunistic pathogens (Murphy et al., 2008). 
The immune system can be subdivided into two major components: the innate and 
the adaptive immune responses. These two arms of the immune system are 
equipped with a diverse set of mechanisms to defend the body. The innate response 
represents the first line of immediate host defense against pathogens and most 
infections are cleared within hours by the defense mechanisms of the innate system. 
Once the innate response fails to contain the infection the adaptive immune response 
comes into play. Adaptive immunity relies on the clonal expansion of antigen specific 
cells that target the microorganisms and on the generation of long-lasting memory 
cells that prevent reinfection. For an effective clearing of disease, cooperation of both 
the innate and the adaptive systems is essential (Murphy et al., 2008). 
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3.1.2 The innate immune response 
 
The first barriers that prevent pathogens from invading the body and replicating are 
the skin and mucosal epithelia. But these surface epithelia are not only a physical 
barrier, they also produce chemical components, so called antimicrobial peptides 
(Ganz, 2003) or enzymes to prevent pathogens from growing. The surface pH of the 
epithelia is often changed to a milieu in which the pathogens do not replicate and the 
mucosal epithelia secrete mucus that keeps pathogens from adhering. In addition, 
most epithelia are covered by a layer of nonpathogenic commensal bacteria that 
compete with pathogenic bacteria for nutrition and space (Murphy et al., 2008).  
Once the pathogens overcome this first barrier they can be recognized and 
phagocytosed by tissue resident macrophages, dendritic cells (DCs) or if they enter 
the blood stream by neutrophils. After phagocytosis, the pathogens are destroyed by 
a mixture of toxic products and enzymes. Phagocytic cells use different specialized 
receptors to recognize pathogens and induce a proper immune response. Some 
receptors recognize repeating patterns found on the surface of microorganisms, 
others help to distinguish different types of pathogens. Receptor ligation can trigger 
different effects: phagocytosis, complement activation or induction of cytokines, 
chemokines and co-stimulatory molecules (Akira et al., 2006; Murphy et al., 2008). 
The release of cytokines and chemokines results in local inflammation which then 
induces the expression of cell-adhesion molecules on the endothelial cells of local 
blood vessel cells. Movement of blood leukocytes, e.g. neutrophils and monocytes, is 
slowed down by the cell-adhesion molecules and the chemokines attract the cells to 
the site of inflammation. Depending on the signals they receive monocytes can either 
differentiate into macrophages or DCs (Murphy et al., 2008).  
The complement system is one of the major components of the innate immune 
response. The complement system consists of plasma proteins that get activated 
directly by the pathogen or indirectly through pathogen bound antibodies. Activation 
of complement leads to a cascade of reactions and generates effector components 
with different functions. Fragments of the complement components are involved in 
opsonization of pathogens, chemotactic attractions of phagocytic cells, activation of 
leukocytes and cytolysis of pathogens through the membrane attack complex 
(Murphy et al., 2008; Rus et al., 2005). 
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Natural killer (NK) cells are the effector lymphocytes of the innate response. They are 
activated by interferons and macrophage-derived cytokines as a response to 
intracellular infections, especially by viruses. NK cells are able to discriminate healthy 
from infected cells through a variety of cell surface activating and inhibitory receptors. 
The activating NK cell receptors sense alert ligands that mark cells under distress. 
Inhibitory NK cell receptors detect constitutively expressed major histocompatibility 
complex (MHC) class I molecules and other "self-signals". Signaling from the 
inhibitory receptors usually overwrites the signal from the activating receptors. MHC 
class I is a receptor that randomly presents self-peptides produced within the cell. 
Expression of MHC class I and other self-ligands is often lost upon cellular stress. 
Once the absence of the self-ligands is detected, this induces killing of the target cell 
though cytotoxic granules. NK cells serve to contain the infection until the adaptive 
immune response, and in particular cytotoxic T lymphocytes (CTLs), clear the 
infection (Murphy et al., 2008; Vivier et al., 2008).  
 
3.1.3 The adaptive immune response 
 
If the innate immune response fails to eliminate the pathogen, adaptive immunity gets 
induced. T cells are the central cells of the adaptive immunity. After their 
development in the thymus the naïve T cells start to circulate in the bloodstream and 
the peripheral lymphoid organs. The naïve T cells continue to recirculate until they 
meet their specific antigen presented as a peptide:MHC complex by an antigen 
presenting cell (APC). MHC class I molecules are found on almost every nucleated 
cell, including APCs, and serve to present peptides from cytosolic produced proteins 
to T cells. MHC class II molecules are normally expressed by APCs and present 
peptides of extracellular proteins mainly derived from phagocytosed and digested 
pathogens. DCs are by far the most important APCs for the activation of T cells. After 
contact to the pathogen at the side of infection, DCs will migrate to lymph nodes (LN) 
and spleen, where they present the pathogen-peptide:MHC complexes to the T cells. 
T cells recognize the peptide:MHC complex with their surface T cell receptor (TCR) 
and CD4/CD8 molecules. In addition to the specific antigen, the T cells need 
CD28-dependent co-stimulation through CD80 or CD86 and cytokines to differentiate 
and proliferate into effector T cells that help to remove the pathogen. Depending on 
Introduction 
6 
the kind of pathogen, the T cells will differentiate into different effector T cells 
subtypes (Murphy et al., 2008).  
CD8+ naïve T cells recognize a complex of MHC class I and intracellular peptide. 
CD8+ T cells are specialized in the detection of intracellular pathogens, in particular 
viruses. Upon stimulation they will differentiate into CTLs, which kill infected host 
cells through the release of cytotoxic granules that contain among others granzymes 
and perforin (Jenkins and Griffiths, 2010).  
The TCR of CD4+ T cells recognizes a complex of a pathogen peptide and a MHC 
class II molecule. Upon stimulation naïve CD4+ T cells can differentiate into different 
CD4 effector subsets. Currently, CD4 effector subsets are mainly differentiated into T 
helper (TH) 1, TH2 and TH17.  
The TH1 subset is induced through the cytokines interleukin 12 (IL-12) and interferon 
γ (IFNγ) and is characterized by the expression of the transcription factor T-bet and 
the release of IL-2 and IFNγ. TH1 cells are associated with cell-mediated immunity 
and have two different functions. Certain bacteria, such as mycobacteria can upon 
phagocytosis through macrophages evade the usual killing mechanisms and instead 
replicate inside the macrophages. One role of TH1 cells is to detect such infected 
macrophages, stimulate them further and thereby enable killing of the intracellular 
bacteria. The second function of TH1 cells is to stimulate antibody production and 
also class switching of B cells. B cells activated through TH1 cells will produce 
opsonizing antibodies, primary Immunoglobulin G (IgG).  
IL-4 induces TH2 cells, which are characterized by the expression of the transcription 
factor GATA3 and the secretion of IL-4 and IL-5. TH2 cells are also involved in the 
activation and class switching of B cells. The humoral immune response induced by 
TH2 leads to the production of IgM, IgA and IgE antibodies by B cells. Besides 
interaction with T cells, B cells need prior contact with their specific antigen via their B 
cell receptor molecule to get activated. The activating T cells need to have the same 
antigen specificity as the activated B cells. Upon activation, B cells proliferate and 
differentiate either into antibody-secreting plasma cells or into memory B cells. 
Antibodies secreted by B cells serve different functions: they can neutralize a 
pathogen, facilitate uptake by phagocytes or activate the complement system 
(Murphy et al., 2008).  
A combination of the cytokines transforming growth factor β (TGFβ) and IL-6 leads to 
differentiation into the TH17 lineage. TH17 cells are characterized by the expression 
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of RORγT and the secretion of IL-17. TH17 cells are usually the first T cells that 
emerge during infections. They induce massive tissue inflammation, recruit 
neutrophils to the side of infection and thereby help to clear infection with different 
pathogens (Korn et al., 2009).  
NKT cells are innate-like mostly NK1.1+CD4+ thymocytes that develop in the thymus 
and express a TCR. Development of these cells in the thymus is independent of 
MHC class I and II molecules but instead dependent on MHC–like CD1d molecules 
which bind self- and microbial-glycosphingolipids. NKT cells proliferate and acquire 
an effector/memory phenotype prior to the emigration from the thymus. The 
stimulation of NKT cells through glycosphingolipids leads to the secretion of IFNγ, IL4 
and chemokines and to the activation of DCs. DCs in turn prime adaptive CD4 and 
CD8 T cell responses. In addition, NKT cells can activate NK cells and activate 
antibody production by B cells (Bendelac et al., 2007). 
TH1, TH2, TH17 and NKT cells all carry a TCR consisting of one α- and one β-chain. 
In contrast to those cells, γδT cells have a TCR consisting of a γ- and δ-chain. 
γδT cells are especially found within epithelial tissues, e.g. skin, but also in lymphoid 
tissues. These T cells have been described as innate-like since their TCRs have only 
a limited diversity compared to the αβTCRs and it seems that they are not depending 
on MHC interaction for activation. It was suggested that those cells recognize 
molecules that are derived from the epithelia themselves as a result of cellular stress 
(Murphy et al., 2008; Thedrez et al., 2007).  
Last but not least, regulatory T (Treg) cells have to be introduced as an important part 
of the adaptive immune system. These cells maintain the tolerance towards 
self-antigens, regulate immune reactions and immune homeostasis through their 
suppressive mechanisms (Vignali et al., 2008). Treg cells are characterized by high 
surface expression of the IL-2 receptor molecule CD25 and by expression of the 
transcription factor forkhead box P3 (FOXP3), which was identified as essential for 
proper Treg cell function (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003). 
Treg cells are in the focus of this dissertation and their generation and function will be 
explained in the following chapters of this introduction.  
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3.2 Generation of T cells 
 
3.2.1 The multi-step process of thymic T cell selection 
 
All T cells are thymus derived. T cell progenitors develop from pluripotent 
hematopoietic stem cells in the bone marrow and migrate to the thymus where they 
differentiate into the different types of mature T cells. At first, these multi lymphoid 
progenitors do not express the TCR or the surface co-receptors CD4 and CD8. Due 
to the lack of CD4 and CD8 surface expression these precursors are termed double-
negative (DN) cells. The DN precursors are divided into DN1-DN4 developmental 
stages depending on their CD44 and CD25 expression. Between the DN2 and DN3, 
stages the first gene rearrangement takes place, which results in the expression of 
TCRβ, TCRγ and TCRδ chains. At this point, commitment to either αβT or γδT cell 
lineage takes place and the development of γδT cell branches off from the αβT cell 
development (Ceredig and Rolink, 2002). TCRβ rearrangement leads to the 
expression of a pre-TCR complex, composed of the TCRβ chain, a pre-Tα molecule 
and CD3. Successful signaling of the pre-TCR allows the precursors to pass the DN3 
checkpoint and leads to proliferation at the late DN3 and early DN4 stage (von 
Boehmer, 2005). Finally the cells start to rearrange their Tcra gene resulting in the 
expression of an αβTCR on the cell surface. In addition, expression of CD4 and CD8 
co-receptors is induced. These CD4+CD8+ T cell precursors are referred to as 
double-positive (DP) cells. For further maturation into specialized CD4 or CD8 single-
positive (SP) cells, the DP cells need to undergo positive and negative selection 
processes (von Boehmer and Melchers, 2010). During positive selection, cortical 
thymic epithelial cells (cTECs) present MCH class I and II molecules to the DP cells. 
DP cells that fail to recognize MHC molecules with their TCR are eliminated through 
apoptosis. This selection step also decides whether the cells will commit to the CD4 
or CD8 T cell lineage. DP precursors that interact well with MHC class II will commit 
to a CD4 T cell fate, the ones interacting well with MHC class I will commit to the CD8 
T cell lineage (Taniuchi, 2009). Once the cells have been positively selected, 
medullary thymic epithelial cells (mTECs) and other thymic APCs will present them 
with a broad range of self-peptide:MHC complexes. mTECs are capable of 
promiscuous gene expression, which is facilitated by the transcription factor AIRE. If 
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the affinity of a TCR toward these self-antigens is too strong, the precursor will be 
driven into apoptosis. Thereby negative selection helps to eliminate potentially 
autoreactive T cells (Klein et al., 2014). To escape negative selection, conventional 
CD4+ or CD8+ T cells need to express a TCR with low to moderate affinity towards 
self-antigen, while CD4+ T cells committed to the Treg cell lineage typically express a 
TCR with a higher affinity for self-antigens (Hogquist, 2001).  
 
3.2.2 Thymic Treg cell generation 
 
The majority of the Treg cell population is thymic derived. The importance of thymic 
derived Treg (tTreg) cells was first noted in thymectomy experiments. Thymectomy in 
newborn mice on day 3 but not day 7 resulted in severe autoimmune disease. This 
observation was later explained by the fact that Treg cells which start to migrate from 
the thymus into the periphery after day 3 are essential for inducing and maintaining 
self-tolerance (Asano et al., 1996; Fontenot et al., 2005a). Hence the thymus 
establishes immune tolerance not only by eliminating potentially autoreactive T cells 
from the conventional T (Tconv) cell pool, but also by generating the tolerance 
inducing population of tTreg cells (Hsieh et al., 2012). Different molecular and cellular 
aspects contribute to the differentiation of Treg cells in the thymus and will be 
introduced in the following paragraphs.  
In the past years several experimental approaches addressed the question if TCR 
self-reactivity is the driving force behind tTreg generation with differing results. The 
first hints for a role of TCR specificity came from experiments that used mice which 
only expressed a transgenic TCR with specificity for chicken ovalbumin. CD4+CD25+ 
Treg cells were completely absent from the thymi of these mice (Itoh et al., 1999). 
Later studies showed that for the generation of tTreg cells, the matching cognate 
antigen needs to be present in the TCR-transgenic mouse (Apostolou et al., 2002; 
Jordan et al., 2001; Knoechel et al., 2005). Comparative analysis of the TCR hyper 
variable complementarity determining region 3 (CDR3) repertoires between Tconv and 
Treg cells from mice with limited TCR diversity showed only little overlap of the 
sequences from the two subsets, also indicating an important role of TCR specificity 
in tTreg cell selection (Hsieh et al., 2004; Pacholczyk et al., 2006; Wong et al., 2007). 
In line with the hypothesis that part of tTreg TCRs cells recognize self-antigen, one 
study identified a Treg TCR that appears to be specific for skin antigen (Killebrew et 
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al., 2011). Controversially, studies using other TCR-transgenic mouse models 
detected that expression of the tTreg TCRs resulted in negative selection rather than 
tTreg cell generation or increased frequencies of tTreg cells due to preferential survival 
of tTreg cells (Shih et al., 2004; van Santen et al., 2004). In contrast to the reports 
mentioned above, one other study of TCR repertoires detected a large overlap of the 
Tconv and Treg cell TCR sequences and suggested that several Treg cell TCRs 
recognize foreign antigens (Pacholczyk et al., 2007). As an alternative route to the 
selection by TCR specificity it was proposed that induction of the tTreg cell lineage 
could at least partially occur at the DN cell level (Pennington et al., 2006). Although 
controversially discussed for years, the current evidence is in favor of a role of TCR 
specificity in tTreg cell selection. 
Besides TCR specificity, intraclonal competition is a factor described to play a role in 
tTreg cell differentiation. Studies using transgenic mice that express the naturally 
occurring TCRs of tTreg cells showed that the factors required for tTreg cell 
development are limited (Bautista et al., 2009; Leung et al., 2009). These results 
suggested that access to the tTreg cell lineage is in part restricted by the number of 
thymic APCs and the amount of antigen presented.  
Another factor that determines tTreg cell selection is TCR signaling strength. The 
current model suggests that the interaction avidity that drives commitment into the 
tTreg cell lineage lies higher than that of Tconv cell selection and even slightly overlaps 
the area of negative selection. It was observed in a TCR-transgenic mouse model 
that recognized an expressed cognate antigen with either high or low affinity, that the 
antigens recognized with a low affinity did not drive Treg cell development (Cozzo 
Picca et al., 2011). These results demonstrated the importance of the interaction 
affinity between TCR and peptide-MHC in tTreg cell selection. Experiments using a 
transgenic mouse with green fluorescent protein (GFP) under the control of the 
Nr4a1 promoter gave interesting insights into the signaling strength required for tTreg 
cells differentiation. In these mice, TCR stimulation results in activation of the Nr4a1 
gene. Hence, GFP expression is directly correlated with the TCR signaling strength. 
GFP levels detected in Foxp3+ Treg cell were higher than those detected in the Foxp3- 
cells indicating that differentiation into the tTreg cell lineage requires higher signaling 
strength (Moran et al., 2011).  
In addition to the TCR signaling strength itself, co-stimulation via CD28 seems to be 
involved in the generation of Treg cells. Frequencies of generated tTreg cells were 
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massively decreased under CD28-deficient conditions (Salomon et al., 2000; Tai et 
al., 2005).  
Based on the current knowledge, a two-step model of Treg cell differentiation was 
proposed (Figure 1) (Lio and Hsieh, 2008). It was previously noted that CD4SP 
CD25+FOXP3- cells preceded the generation of CD4SP CD25+FOXP3+ cells and that 
CD4SP CD25+FOXP3- precursors did not depend on TCR stimulation to up regulate 
FOXP3 (Fontenot et al., 2005b; Lio and Hsieh, 2008). While up regulation of FOXP3 
in the CD4SP CD25+FOXP3- precursors is independent of TCR signaling, the two 
common-γ-chain cytokines, IL-2 and IL-15 are essentially needed factors (Lio and 
Hsieh, 2008; Wirnsberger et al., 2009). In conclusion, during the first step, the "early" 
precursor defined as CD4SP CD69+CD25-FOXP3- differentiates in a TCR and 
co-stimulation-dependent manner into the "late" precursor characterized as CD4SP 
CD69+CD25+FOXP3-. The second step involves the TCR independent, but IL-2- and 
IL-15-dependent differentiation of the late Treg precursor into a mature CD4SP 
CD25+FOXP3+ tTreg cell (Lio and Hsieh, 2008; Wirnsberger et al., 2009). 
 
  
Figure 1: A two-step model for tTreg cell differentiation. Recognition of self-peptide–MHC class II 
complexes with sufficiently high per cell avidity for tTreg cell selection, in the presence of co-stimulation 
leads to differentiation of the "early" precursor cells (CD4SP CD69+CD25-FOXP3-; here immature SP 
CD4+ T cell) into the "late" precursors (CD4SP CD69+CD25+FOXP3-; here FOXP3–CD25+ Treg cell 
precursors). At this point, the late Treg precursor does not require further TCR stimulation for the 
expression of FOXP3. Instead, cytokine signals mediated by IL‑2 and IL‑15, facilitate the induction of 
FOXP3 expression. Reprinted by permission of Macmillan Publishers Ltd: Nat Rev Immunol, March 
2012 (doi: 10.1038/nri3155) (Hsieh et al., 2012). 
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The molecular mechanisms downstream of TCR signaling are crucial for tTreg 
differentiation since the expression of Foxp3 is essential for the suppressive function 
of Treg cells. Several pathways get activated downstream of TCR signaling and are 
involved in Foxp3 gene regulation (Delacher et al., 2014). Activation of the 
AKT-mTOR pathway was demonstrated to have an inhibitory effect on Foxp3 
initiation (Haxhinasto et al., 2008). While Ca2+ signaling seems to be involved in tTreg 
differentiation (Oh-Hora et al., 2013), its downstream transcription factor, the nuclear 
factor of activated T cells (NFAT) which binds to the Foxp3 promoter, seems to be 
mainly important in the generation of TGFβ induced peripheral Treg cells (Vaeth et al., 
2012). The NF-кB pathway on the other hand was identified as crucial for the 
initiation of Foxp3. cREL, a transcription factor of the NF-кB family was suggested as 
a pioneer transcription factor that binds to the conserved non-coding sequence 3 
(CNS3) promoter region and thereby initiates Foxp3 expression (Schuster et al., 
2012; Zheng et al., 2010). The members of the Nr4a family were recently identified 
as critical transcription factors for the regulation of Foxp3, as the triple knock-out of 
Nr4a1, Nr4a2 and Nr4a3 resulted in the complete loss of Foxp3 expression. It was 
suggested that these factors help to translate TCR signaling strength into Foxp3 
induction (Sekiya et al., 2013). 
 
3.2.3 Generation of peripheral Treg cells 
 
A small part of the Treg cell population is generated in the periphery. These so called 
peripheral derived Treg (pTreg) cells are former FOXP3- Tconv cells that converted to 
the Treg cell lineage. Induction of pTreg cells involves soluble factors in the 
microenvironment like TGFβ and IL-2, in combination with activation through 
specialized APCs (Yadav et al., 2013). pTreg cells participate in the control of immune 
responses at sites of inflammation and are thought to complete the Treg pool through 
the induction of tolerance against non-pathogenic foreign antigens, including 
commensal bacteria, food and fetal antigens (Josefowicz et al., 2012; Samstein et al., 
2012; Yadav et al., 2013). The transcription factor HELIOS of the Ikaros family was 
suggested as a marker that distinguishes tTreg from pTreg cells, as it is only expressed 
by the thymic derived tTreg cells (Thornton et al., 2010).  
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3.3 Features of Treg cells  
 
3.3.1 Functional mechanisms of Treg cells 
 
Treg cells which represent about 10 percent of the CD4+ T cell population have 
emerged as an essential part of the immune system more than a decade ago. Their 
relevance became clear when the human immunodysregulation polyendocrinopathy, 
enteropathy X‑linked (IPEX) autoimmune diseases was connected to a mutation in 
the Foxp3 gene, the transcription factor that drives Treg cell development (Bennett et 
al., 2001). Likewise, scurfy mice that carry a mutated Foxp3 gene suffer from a lethal 
autoimmune disease (Brunkow et al., 2001). Furthermore impaired function of Treg 
cells was linked to other autoimmune conditions, including lupus, type 1 diabetes, 
rheumatoid arthritis and multiple sclerosis (Ehrenstein et al., 2004; Horwitz, 2010; 
Lindley et al., 2005; Viglietta et al., 2004). Treg cells are important for the maintenance 
of immune tolerance throughout life. Depletion of Treg cells from healthy adult mice 
results in catastrophic autoimmune disease and death within weeks (Kim et al., 
2007). But how do Treg cells mediate immune tolerance? The following chapter will 
explain some of the basic mechanisms used by Treg cells that induce tolerance at 
different levels. 
Treg cell-mediated suppressive mechanisms can be divded into four different 
categories: 1) suppression by inhibitory cytokines, 2) suppression by cytolysis, 3) 
suppression by metabolic disruption and 4) suppression by modulation of DC 
maturation and function (Figure 2) (Vignali et al., 2008).  
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Figure 2: Basic mechanisms used by Treg cells. Depiction of the various Treg cell mechanisms 
centered around four basic modes of action. a) Inhibitory cytokines include IL-10, IL‑35 and TGFβ. b) 
Cytolysis includes granzyme A- and B-dependent and perforin-dependent killing mechanisms. c) 
Metabolic disruption includes high-affinity CD25-dependent cytokine deprivation mediated apoptosis; 
cAMP mediated inhibition; CD39 and/or CD73 generated adenosine and A2AR mediated 
immunosuppression. d) Targeting DCs includes mechanisms that modulate DC maturation and/or 
function such as LAG3–MHC-class-II mediated suppression of DC maturation; and CTLA-4–
CD80/CD86 mediated induction of IDO, which is an immunosuppressive molecule made by DCs. 
Reprinted by permission of Macmillan Publishers Ltd: Nat Rev Immunol, Jul 2008 (doi: 
10.1038/nri2343) (Vignali et al., 2008). 
 
Release of inhibitory cytokines including IL-10, IL-35 and TGFβ is one of the Treg cell 
suppressive mechanisms. Release of IL-10 by Treg cells has inhibitory effects on Tconv 
cells and it was demonstrated to be particularly important for the control of 
inflammatory disease in barrier tissue such as colon and lungs (Rubtsov et al., 2008). 
The Treg cell-mediated suppression by soluble TGFβ or surface-tethered TGFβ is a 
controversial topic. The role of TGFβ seems to depend on the specific disease and 
experimental settings (Vignali et al., 2008). Glycoprotein-A repetitions predominant 
(GARP) was identified as the molecule that tethers TGFβ in a latent form to the 
surface of Treg cells (Probst-Kepper and Buer, 2010). Surface-tethered TGFβ was 
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suggested to induce tolerance by converting Tconv into FOXP3+ pTreg cells with 
suppressive functions (Andersson et al., 2008). The inhibitory cytokine IL-35 is 
preferentially expressed and secreted by Treg cells and has an inhibitory effect on 
Tconv cells. It was suggested that IL-35 is required for maximal Treg cell suppressive 
function (Collison et al., 2007). 
Another mechanism of Treg cell-mediated suppression is induction of apoptosis in 
target cells by cytolysis. Human Treg cells were demonstrated to kill target cells in a 
granzyme A and perforin-dependent manner (Grossman et al., 2004), while mouse 
Treg cells were shown to induce granzyme B-dependent apoptosis in Tconv but also B 
cells (Gondek et al., 2005; Zhao et al., 2006). 
Among the different suppressive mechanisms of metabolic disruption, CD25 
expression has been well studied. High surface expression of CD25 is one of the Treg 
cell phenotypical hallmarks and CD25 expression might also contribute to the Treg cell 
suppressive capacity by consuming local IL-2 and thereby starving other Tconv cells 
that depend on IL-2 for survival (Oberle et al., 2007). The cell surface ectoenzymes 
CD39 and CD73 are preferentially expressed by Treg cells and mediate Treg cell 
suppression. The ectoenzymes generate pericellular adenosine which can suppress 
Tconv cell and DC function through binding and activating the adenosine receptor 2A 
(A2AR) (Deaglio et al., 2007). In addition, Treg cells can inhibit Tconv cells by 
transferring the second messenger cyclic adenosine monophosphate (cAMP) directly 
through gap junctions into Tconv cells (Bopp et al., 2007).  
DC cells are required for the activation of Tconv cells and Treg cell-mediated inhibition 
of DC maturation and function thereby indirectly suppresses Tconv cells. The T cell 
surface molecule cytotoxic T lymphocyte associated protein 4 (CTLA-4) is an 
essential molecule for Treg cell-mediated suppression of DCs. Treg cell specific loss of 
CTLA-4 results in multi organ autoimmunity (Wing et al., 2008). It was suggested that 
interaction between CTLA-4 and CD80/CD86 leads to trans-endocytosis of the co-
stimulatory molecules CD80 and CD86 by Treg cells (Qureshi et al., 2011). In 
addition, CTLA-4 engagement of Treg cells with DCs was shown to induce expression 
and release of indoleamine 2, 3-dioxygenase (IDO), which results in the suppression 
of Tconv cells (Mellor and Munn, 2004). Another cell surface molecule of Treg cells 
involved in the control of DC function is the CD4 homologue lymphocyte activation 
gene 3 (LAG3). LAG3 interacts with MHC class II molecules on DCs and thereby 
blocks DC maturation (Liang et al., 2008). Furthermore, most Treg cells express the 
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surface molecule neuropilin 1 (NRP1). NRP1 is involved in mediating prolonged 
interactions between Treg cells and DCs. The prolonged interaction period compared 
to Tconv cells might give them an advantage for the modulation of DC cell function 
(Sarris et al., 2008). Indeed, blocking of NRP1 leads to reduced Treg cell suppressive 
function (Solomon et al., 2011).  
Treg cells are equipped with a variety of different immunosuppressive mechanisms, 
which they can use for the regulation of inflammatory conditions or immune 
homeostasis. The importance of these different mechanisms always depends on the 
character of the inflammation and the specific tissue environment (Campbell and 
Koch, 2011).  
 
3.3.2 Treg cell stability and plasticity 
 
The Treg cell phenotype is mainly defined by suppressive capacity and high 
expression of CD25 and FOXP3. Under physiological conditions these markers are 
stably expressed, but Treg cells have been reported to lose the expression of FOXP3 
under inflammatory or pathogenic conditions and acquire a TH cell phenotype (Zhou 
et al., 2009). When CD25low Foxp3+ Treg cells are transferred into a lymphopenic host, 
a part of the cells also lose expression of CD25 and FOXP3 and differentiate into TH 
cells (Duarte et al., 2009; Komatsu et al., 2009). Upon TCR stimulation, such ex-Treg 
cells are capable of re-expressing FOXP3 and re-gaining suppressive capacity 
(Miyao et al., 2012). Human and mouse Tconv cells have been demonstrated to 
transiently express FOXP3 following activation (Hori, 2011; Sakaguchi et al., 2010). 
But the fact that these cells express FOXP3 does not turn them into a Treg cell with 
suppressive capacities. While FOXP3 is essential, evidence suggests that other 
transcription factors are needed for the manifestation of the characteristic Treg cell 
phenotype (Fu et al., 2012).  
Treg cells also show the ability for further differentiation following initial activation. Treg 
cells can use the same transcription factors used by naïve Tconv cells for 
differentiation into effector T cells. Expression of T-bet allows Treg cells to traffic into 
areas of TH1 inflammation and to suppress T cells of the TH1 phenotype (Koch et al., 
2009). Similarly, expression of the transcription factors IRF4 and STAT3 by Treg cells 
was needed for efficient TH2- and TH17-mediated inflammation respectively 
(Chaudhry et al., 2009; Zheng et al., 2009). These reports suggest that Treg cells 
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have the ability to adapt to special microenvironments by using mechanisms 
comparable to those of Tconv cells. 
Recently, epigenetics have come more into the focus of Treg cell research. 
Demethylation patterns are inheritable, stable and linked to gene expression. During 
Treg cell differentiation in the thymus characteristic demethylation patterns are 
induced upon TCR stimulation. tTreg cells retain a specific demethylation pattern, 
particularly in Treg cell function-associated genes like Foxp3, Helios or Ctla-4 (Ohkura 
et al., 2012). Stable expression of the Foxp3 gene has been linked to demethylation 
of CpG islands within the regulatory CNS2 region of the Foxp3 locus (Polansky et al., 
2008; Zheng et al., 2010). One of the differences between tTreg and pTreg cells lies 
within the methylation status of the CNS2 region of the Foxp3 gene. pTregs that fail to 
demethylate the CNS2 region eventually lose FOXP3 (Hori, 2011; Miyao et al., 
2012).  
 
3.4 Transcription factor 7 and the immune system 
 
3.4.1 The TCF7/LEF1 family 
 
The high mobility group (HMG) box family member, transcription factor 7 (TCF7), 
also known as T cell specific transcription factor 1 (TCF1) was first identified as a 
possible candidate for the T cell maturation process in 1991 (van de Wetering et al., 
1991). Several TCF7 isoforms exist, which can be roughly subdivided into short (25-
40 kDA) and long (42-60 kDA) isoforms. The long isoforms consist of: 1) a nuclear 
localization sequence (NLS), 2) a 5’-TCAAAG consensus sequence recognizing 
HMG domain, 3) a Groucho protein binding domain known to mediate transcriptional 
repression and 4) a β-catenin binding domain which mediates transcriptional 
activation. Short TCF7 isoforms lack the β-catenin binding domain and are therefore 
constant transcriptional repressors (Maier et al., 2011; Van de Wetering et al., 1996).  
Another member of the HMG box family lymphoid enhancer binding factor 1 (LEF1) 
shares a nearly identical HMG domain and shows, in general, a high level of 
sequence homology with TCF7 (Van de Wetering et al., 1996). Binding sites for 
TCF7 and LEF1 have been identified in transcriptional control regions of different 
genes, including CD4, TCRβ and TCRγ (Okamura et al., 1998). Both TCF7 and LEF1 
Introduction 
18 
are expressed during T cell differentiation and in mature T cells (Verbeek et al., 
1995).  
 
3.4.2 TCF7 and T cell development 
 
The essential role of TCF7 in thymic T cell development was first noticed when 
Tcf7-deficient (Tcf7-/-) mice showed greatly reduced numbers of thymocytes (Verbeek 
et al., 1995). Originally a neo gene insertion was performed at 2 different locations 
within the Tcf7 gene site, but only the insertion into exon 7 Tcf7∆VII, which encoded 
for the HMG domain, resulted in the severe phenotype. Since the generation of Tcf7-/- 
mice, several defects in thymocyte development from the DN to the SP stage have 
been reported. Otherwise healthy young Tcf7-/- mice have an incomplete block of 
thymocyte differentiation at DN and immature SP stages, as β-selection and 
maturation to the DP stage are compromised. Several month old mice have a 
complete block probably at the DN1 stage (Schilham et al., 1998; Staal et al., 2008; 
Verbeek et al., 1995). A double knock-out of Tcf7 and Lef1 resulted in complete block 
of T cell differentiation and demonstrated that TCF7 and LEF1 have partially 
redundant function during thymocyte development (Okamura et al., 1998). The 
importance of the interaction between TCF7 and β-catenin for T cell development 
was experimentally shown. Reconstitution of Tcf7-/- mice with different forms of TCF7 
that can or cannot interact with β-catenin showed that only reconstitution with β-
catenin interacting forms restored T cell development (Ioannidis et al., 2001). 
Furthermore, Cre driven conditional deletion of β-catenin resulted in impaired T cell 
development at the DN stage (Xu et al., 2003). Clearly, β-catenin/TCF7 signaling has 
an important role in T cell development and activation of β-catenin/TCF7 during T cell 
development was implicated downstream of the Notch, Wnt and TCR signaling 
pathways (Kovalovsky et al., 2009; Staal et al., 2008; Weber et al., 2011). In early T 
cell precursors, TCF7 expression is induced through Notch signals and is involved in 
T cell fate imprinting (Weber et al., 2011). Expression of TCF7 at the DP stages 
contributes to the survival of T cell precursors (Ioannidis et al., 2001). To specifically 
look at the influence of the TCF7 and LEF1 in the DP to SP transition, a recent study 
used a Cd4-Cre induced double loss of TCF7 and LEF1 transcription factors. The 
results demonstrated that the double loss impaired CD4 SP generation and promoted 
CD8 SP fate (Steinke et al., 2014). Older Tcf7-/- mice are prone to develop thymic 
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malignant transformations, indicating a role of TCF7 as a T cell specific tumor 
suppressor. It was suggested that TCF7 mediates its tumor suppressive function by 
repression of LEF1 expression, which would propose a so far unappreciated 
interaction beyond T cell development (Tiemessen et al., 2012; Yu et al., 2012).  
 
3.4.3 The role of TCF7 in immune cell function  
 
Although TCF7 was mainly studied in the context of T cell development, TCF7 is also 
implicated in the function and development of immune cells outside of the thymus.  
During helminthic infection the innate group 2 innate lymphoid cells (ILC2) induce 
protective type 2 immunity. Notch-dependent induction of TCF7 is required for the 
development of ILC2 cells (Yang et al., 2013). TCF7 and LEF1 are both involved in 
NK cell development and TCF7 is required for the proper formation of Ly49 receptors 
on NK cells (Held et al., 2003). Upon TCR stimulation in CD4+ T cells, TCF7 induces 
GATA3, inhibits IFNγ expression and thereby promotes TH2 fate (Yu et al., 2009). 
Differentiation of Tcf7-/- CD8+ T cells toward the memory phenotype and persistence 
of CD8+ memory T cells were severely impaired probably due to reduced expression 
of the IL-2 receptor beta chain and reduced levels of the anti-apoptotic molecule B 
cell lymphoma 2 (BCL-2) (Zhou et al., 2010). In TH17 development, TCF7 mediates 
repression of the IL-17 gene by epigenetic modifications. Moreover, TH17 cells from 
Tcf7-/- mice express higher levels of the IL-7 receptor α-chain which might enhance 
their survival and expansion (Ma et al., 2011; Yu et al., 2011). Finally, previous 
reports also studied the role of TCF7 in the function of Treg cells. Forced expression 
of a stable form of β-catenin resulted in enhanced survival of Treg cells (Ding et al., 
2008). Another report stated that Treg cell suppressive function was reduced by the 
activation of β-catenin/TCF7 through Wnt signaling (van Loosdregt et al., 2013). 
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4 Aims of study 
 
Treg cells have emerged as critical control elements of the immune system, as they 
keep the balance between protective immune responses and tolerance.  
In the past, gene expression profiles of Treg cells have been intensively studied, but 
mRNA does not always translate into protein and so far full data sets of Treg cell 
protein expression is missing. As a starting point of this PhD project, we aimed to 
characterize Treg cells at the proteome level and to use this information to identify 
candidate proteins that are implicated in Treg cell development and function. Further, 
we aimed to then use different in vivo and in vitro systems to analyze in detail how 
these candidate proteins are involved in the Treg cell thymic differentiation and 
function.  
Although Treg cells have been studied for years, we still do not fully understand how 
these cells are generated and regulated. A better understanding of Treg cells is crucial 
to find future treatment options that are capable of suppressing or boosting the 
immune response. 
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5 Methods 
 
5.1 Mice 
 
5.1.1 Keeping 
 
Mice were 4-9 weeks old at the time of the experiments. All mice were cared for 
under the specific-pathogen free conditions in the animal facility of the DKFZ. All 
animal experiments were reviewed and approved by the governmental committee for 
animal experimentation in Karlsruhe, Germany.  
 
5.1.2 Breeding 
 
Tcf7-/- mice (mixed 129-C57BL/6 background) (Verbeek et al., 1995) were crossed to 
Foxp3-YFP (Rubtsov et al., 2008) or TEa (Grubin et al., 1997) mice in the DKFZ 
animal facility. Foxp3-GFP mice (Kim et al., 2007) were crossed to a CD45.1 or 
CD90.1 background. For experiments we used littermates as control animals unless 
otherwise indicated. 
 
5.2 Cell culture techniques 
 
5.2.1 Mammalian cell culture 
 
Cells were cultured at 37°C, 5% (v/v) CO2 in complete medium and treated at all 
times under a cell culture hood (Thermo fisher scientific). Cells were split at 1:10–
1:20 depending on the level of confluence. For splitting, cells were washed with PBS 
and detached with trypsin-EDTA solution. Detaching reaction was stopped by adding 
complete medium. Cells were centrifuged and a fraction of cells was seeded in a new 
flask with complete medium. For the determination of cell numbers, cells were 
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counted using a Neubauer chamber (0.1 mm depth) and trypan blue solution. Cell 
count = mean number of cells per square x dilution factor x 104 cells/ml. 
 
5.2.2 Bacterial cell culture 
 
Bacteria were cultured at 37°C in LB-Medium supplemented with antibiotics in a 
bacterial incubator at 180 rpm. Bacteria were prepared for long-term storage at -80°C 
by adding 700µl of glycerol to 300 µl of bacteria. For plasmid production, bacteria 
were lysed and plasmids were purified according to manufacturer’s instructions using 
a Mini or Midi preparation kit (Life technologies). Quality and concentration of the 
isolated DNA plasmids was analyzed using a NanoDrop 2000 (Thermo Fisher 
Scientific). 
 
5.3 Proteomics 
 
5.3.1 Protein digestion, labeling of peptides with stable isotopes and 
fractionation 
 
Cell pellets of FACS-purified cells (about 6 x 105) were snap-frozen in liquid nitrogen. 
After lysis of cells in 0.1 percent RapiGest (Waters)/50 mM ammonium bicarbonate, 
extracted proteins were reduced/alkylated with 5 mM DTT and 10 mM 
iodoacetamide, then digested overnight with sequencing grade modified trypsin 
(Promega). Resulting peptides were dimethyl labeled on a column as previously 
described (Boersema et al., 2009). Briefly, peptides were labeled on SepPak C18 
cartridges (Waters) with the labeling reagent (”light” or “intermediate” using CH2O 
(Fisher) + NaBH3CN (Fluka) or CD2O (Isotec) + NaBH3CN, respectively). In the 
second, third and fourth biological replicate experiments, cell population reagents 
were swapped. The ‘light’ and ‘intermediate’ labeled samples were mixed in 1:1 ratio 
based on cell number. Sample complexity was reduced by fractionating the peptides 
with pH 3-10 IPG strips and 3100 OFFGEL fractionator (Agilent), into 12 fractions. 
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5.3.2 LC-ESI-MS/MS analysis 
 
Peptides were separated by liquid chromatography (LC) using the nanoACQUITY 
UPLC system (Waters) fitted with a trapping column (nanoAcquity Symmetry C18, 
5µm particle size, 180 µm inner diameter x 20 mm length) and an analytical column 
(nanoAcquity BEH C18, 1.7µm particle size, 75µm inner diameter x 200 mm length). 
Peptides were separated on a 120 min gradient and analyzed by electrospray 
ionization-tandem MS (ESI-MS/MS) on an LTQ Orbitrap Velos (Thermo Fisher 
Scientific). Full scan spectra from m/z 300 to 1700 at resolution 30,000 FWHM 
(profile mode) were acquired in the Orbitrap MS. From each full-scan spectra, the 15 
ions with the highest relative intensity were selected for fragmentation in the ion trap. 
A lock mass correction using a background ion (m/z 445.12003) was applied. 
 
5.3.3 Protein identification and quantification 
 
MS raw data files were processed with MaxQuant (version 1.2.0.18) (Cox and Mann, 
2008). Cysteine carbamidomethylation and methionine oxidation were selected as 
fixed and variable modifications, respectively. The derived peak list was searched 
using the built-in Andromeda search engine (version 1.2.0.18) in MaxQuant against 
the Uniprot mouse database (2011.06.21). Initial maximal allowed mass tolerance 
was set to 20 ppm for peptide masses, followed by 6 ppm in the main search, and 0.5 
Dalton for fragment ion masses. A 1 percent false discovery rate (FDR) was required 
at both the protein level and the peptide level. In addition to the FDR threshold, 
proteins were considered identified if they had at least one unique peptide. The 
protein identification was reported as an indistinguishable “protein group” if no unique 
peptide sequence to a single database entry was identified. 
 
5.3.4 Accession number 
 
The MS proteomics data have been deposited to the ProteomeXchange Consortium 
(http://www.proteomexchange.org) via the PRIDE partner repository (Vizcaino et al., 
2013) with the dataset identifier PXD000794. 
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5.4 Tissue sample preparation 
 
5.4.1 Tissue isolation and sample preparation 
 
For tissue isolation, spleen, thymus, and LN (axillary, brachial and inguinal) were 
removed and organs were processed by mashing and filtering to prepare single cell 
suspensions. Ammonium chloride–potassium bicarbonate (ACK) lysis buffer was 
used to lyse erythrocytes in spleen samples. 
 
5.4.2 AutoMACS cell purification 
 
Samples FACS-purified for Treg protein isolation (MS experiments) were first enriched 
for CD25. Samples FACS-purified for Treg precursors and quantitative real-time PCR 
(qPCR) experiments were first depleted of CD8+ cells. For T cell transduction, 
isolation of T cells from spleen and LNs was performed by AutoMACS depletion of 
CD8, CD11b, CD11c, CD19, CD25 and CD49b. For enrichment and depletion, cells 
were labeled with biotin-conjugated antibodies and anti-biotin microbeads (Miltenyi). 
Magnetic cell separation was performed using an AutoMACS Pro Separator 
(Miltenyi). 
 
5.5 Flow cytometry and imaging techniques  
 
5.5.1 Flow cytometry 
 
For surface staining cells were labeled with antibodies/streptavidin for 30 min in 
FACS buffer at 4°C. Intracellular staining of cells was performed after surface 
staining using the intracellular Foxp3 staining buffer set (eBioscience). Cells were 
treated with the fixation buffer for 45 min at 4°C and intracellular stained with 
Fix/Perm buffer and intracellular antibodies for 45 min at room temperature. CD1d 
tetramer staining was performed in the same manner as surface staining. Cells were 
filtered prior to analysis. For compensation unstained or anti-CD4 single stained (in 
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the colors corresponding to the staining panel) spleen cells were used. For most in 
vitro experiments OneComp compensation beads (eBioscience) were used instead. 
Cells were analyzed using the BD Bioscience Canto II LSR Fortessa or LSR II. For 
FACS-purification of cells the BD Biosciences FACSAria I, II or III instruments were 
used. Quality of antibodies was checked using isotype controls. Purity of cell sorts 
was assured through post-sort analysis. FlowJo software (Treestar) was used for the 
analysis of flow cytometry data. 
 
5.5.2 Cell counting 
 
For counting of total thymus subpopulations using beads, AccuCheck+ Counting 
beads (Invitrogen) were added to the sample prior to acquisition. 2 x 104 beads were 
added to 20 percent of the thymus sample. The number of cells in the total thymus 
was calculated according to manufacturer’s instructions (total organ cell count = 
((number of cells counted x number of beads added / average bead count) x dilution 
factor). 
For in vitro experiment cell counts, identical numbers of cells were seeded in all 
wells. All cells were stained and completely acquired by flow cytometric analysis.  
 
5.5.3 Immunofluorescence imaging 
 
Sections (5 µm) from cryo-preserved thymi from Tcf7+/+ and Tcf7-/- mice were 
prepared by step sectioning every 25 µm. Samples were fixed in ice-cold acetone, 
blocked in PBST and stained with antibody against K14 (Covance). Next, sections 
were stained with anti-rabbit-IgG (Jackson ImmunoResearch) and DAPI (Sigma). 
Imaging was performed on an Axio Imager.Z1 (Zeiss). Images were analyzed in 
AxioVision (Zeiss) and Adobe Photoshop (Adobe).  
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5.6 In vitro cell culture assays 
 
5.6.1 Treg precursor differentiation assay 
 
FACS-purified late (CD4SP CD69+CD25+Foxp3-) or early (CD4SP CD69+CD25-
Foxp3-) Treg precursors were seeded at 1 x 105 cells per 96 round-bottom well. Late 
Treg precursors were cultured with human IL-2 100 U/ml (Proleukin S, Novatis) and 
murine IL-15 100 ng/ml (Peprotech Inc.) for 1 day before analysis. Early Treg 
precursors were cultured with human IL-2 100 U/ml, murine IL-15 100 ng/ml and anti-
CD3/CD28 Dynabeads (Invitrogen) at a cell/bead ratio of 1:1 for 3 days prior to 
analysis. 
For Wnt-activation assays, 1 x 105 FACS-purified early Treg precursors were cultured 
for 3 days under the conditions described above. In addition, DMSO dissolved Wnt-
activators 6-Bromoindirubin-3′-oxime (BIO) (biomol) or 6-(2-(4-(2,4-Dichlorophenyl)-
5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-nicotinonitrile 
(CHIR99021) (biomol) were added to the cultures at 1 or 2 µM. Control wells were 
cultured with DMSO concentrations corresponding to the highest DMSO content in 
the wells containing the Wnt activators. 
For the in vitro Treg cell differentiation assay with titration of anti-CD3 stimulus, 96 well 
flat-bottom plates were coated over-night with different concentrations (0.1, 0.25, 0.5 
or 2 µg/ml) of purified anti-CD3 in PBS. Plates were washed with PBS prior to use. 
Purified anti-CD28 10 µg/ml was added together with 1 x 105 precursors, with human 
IL-2 100 U/ml and murine IL-15 100 ng/ml to the culture media. 
 
5.6.2 In vitro iTreg cell and TH17 generation 
 
For in vitro iTreg and TH17 cell generation assays, naïve T cells (CD4+ 
CD62L+FOXP3-) were FACS-purified from spleen and LNs of Foxp3-YFP+ mice. For 
the generation of iTreg cells, the cells were cultured in vitro for 4 days in 96-well round 
bottom plates with human IL-2 100 U/ml (Proleukin S, Novatis), anti-CD3/CD28 
Dynabeads (Invitrogen) at a cell/bead ratio of 1:1 and different concentrations of 
TGFβ (0.3 – 10 ng/ml) (tebu-bio). For the generation of TH17 cells, the cells were 
cultured in vitro for 4 days in 96-well round bottom plates with human IL-2 100 U/ml, 
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anti-CD3/CD28 Dynabeads at a cell/bead ratio of 1:1, TGFβ 10 ng/ml and different 
concentrations of IL-6 (0.3 – 5 ng/ml). 5 h prior to analysis of the TH17 assay, cells 
were restimulated with PMA 50 ng/ml (Biomol), Ionomycin 1 µg/ml (Biomol) and 
Brefeldin A 1:1000 (Biozol Diagnostica). Cells were analyzed by flow cytometry at the 
end of the culture period.  
 
5.6.3 Retroviral T cell transduction 
 
Phoenix-ECO cells were calcium-phosphate transfected either with a Murine Stem 
Cell Virus (MSCV)-Ctrl construct (CD90.1 expression only) or a MSCV-Foxp3 
construct (CD90.1 and Foxp3 expression). For calcium-phosphate transfection 
Phoenix-ECO cells were seeded at a density of 4 x 105 cells per gelatin-coated 6-well 
and cultured overnight. Transfection solution (500 µl) contained per well: 3 µg 
MSCV-vector, 1 µg pCL-Eco, 30 µl 2 M CaCl2 solution, 250 µl 2x HBS and X µl of 
H2O (adds up to 500 µl). After vigorous mixing, transfection solution was rapidly 
added to the Phoenix-ECO cells. Medium was exchanged on the following day. 
Supernatants containing MSCV retroviral particles were harvested at day 3 after 
transfection. Phoenix-ECO transfection efficiency was controlled by flow cytometric 
analysis of CD90.1 expression.  
24-well plates were prepared for T cell culture by coating first with goat-anti-hamster 
IgG (MP Biomedicals) in PBS overnight at 4°C. Secondly wells were coated with 
purified anti-CD3 0.1 µg/ml (BioLegend) and anti-CD28 1 µg/ml (BioLegend) in PBS 
for 4 h at 4°C. For T cell isolation LN and spleen cells were depleted of CD8, CD19, 
CD11b, CD11c, CD25 and CD49b using AutoMACS Pro Separator (Miltenyi). T cells 
were seeded at 2.5 x 106 per 24 well on the pre-coated wells. IL2 (20U/ml) was 
added to the T cell culture at all times. T cells were spin-transduced for 90 min at 
32°C with 3 ml of fresh viral supernatants containing Polybrene 16 µg/ml 40 ± 2 
hours after the start of T cell stimulation. Viral supernatants were exchanged for fresh 
medium. Retrovirally transduced T cells were analyzed 3 days after transduction. 
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5.7 PCR techniques 
 
5.7.1 Standard PCR for genotyping 
 
For genotyping, PCR was performed with adequate primers (listed below) on lysed 
mouse tissue samples according to the protocols from animal providers. Standard 
PCR reactions were performed using a Mastercycler Pro S (Eppendorf). After PCR 
quantification, loading buffer was added and samples were loaded onto ethidium 
bromide containing agarose gels, together with a 2-Log DNA ladder (New England 
Biolabs). Separation of DNA fragments was performed at 80-140 V. A UV gel 
documentation system (Herolab) was used to visualize DNA fragments. 
 
5.7.2 RNA isolation and cDNA synthesis 
 
Cells of interest were FACS-purified (1 – 5 x 104 cells) into 0.5 ml of TRIzol (Life 
technologies) and frozen at -80°C until further processing. 125 µl of chloroform was 
added to each sample. Samples were then vigorously shaken for 15 s, incubated for 
3 min at RT and centrifuged (20 min, 4°C, max speed). Following centrifugation the 
clear phase was carefully transferred to a new tube, 300 µl of isopropanol were 
added, the mixture was incubated for 10 min at RT and stored at -80°C overnight. 
After thawing 1µl of GlycoBlue was added to the samples and samples were 
incubated for 3 min at RT. Following centrifugation (20 min, 4°C, max speed), 
supernatants were carefully removed and the blue RNA pellet was washed 75 % 
ethanol (v/v). After centrifugation (15 min, 4°C, max speed) the supernatant was 
completely removed and the pellet was air-dried at RT. Next, the RNA pellet was 
dissolved in 10 µl nuclease free H2O. For cDNA synthesis, the SuperScript reverse 
transcriptase (Invitrogen) and oligo(dT) primers were used according to 
manufacturer’s instructions.  
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5.7.3 Sybr green quantitative real-time PCR 
 
cDNA samples were analyzed by quantitative real-time PCR using the Power SYBR 
Green master mix (Life technologies) and the ViiA7 instrument (Life technologies). 
Appropriate primers for Hprt and Tcf7 were used. Primer sequences are listed below. 
mRNA (gene X) abundance was quantified as percent relative to the expression of 
Hprt by the change-in-threshold method (100*(relative expression = 2^(CT(gene X) − 
CT(Hprt)))). Prior to use all qPCR primers were tested by serial dilutions, efficiency 
testing and melting curve analysis.  
 
5.8 Bioinformatic and statistical analysis 
 
5.8.1 Proteomics and RNA microarray 
 
Statistical analysis was performed for the proteins quantified in at least two replicates 
using the Limma package in R/Bioconductor (Gentleman et al., 2004; Smyth, 2004). 
Proteins with an adjusted p-value lower than 0.05 were considered to be differentially 
expressed between Treg and Tconv cells. Network analysis was done using STRING 
(Jensen et al., 2009) and visualization was performed in Cytoscape v2.8 (Shannon et 
al., 2003). 
Treg specific genes (over- and under-represented) were identified based on RNA 
micro-array expression data that we published earlier (Feuerer et al., 2010; Hill et al., 
2007). Treg and Tconv cells from LN and thymus were included. Genes more than 1.5-
fold differential expressed between Treg and Tconv were considered significant different 
(Student's t-test, two-tailed, p < 0.05). Generated gene lists were cross-referenced 
with our proteomic data based on gene names and used for further analysis. 
 
 
 
 
 
Methods 
30 
5.8.2 General statistical analysis 
 
Statistical analysis of experimental data was performed using Prism software 
(GraphPad) or Excel (Microsoft). Employed statistical tests and corresponding 
parameters are mentioned in the respective figure legends. Results were considered 
statistically significant if p-values were less than 0.05. 
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6 Materials 
 
6.1 Mice 
 
Name Official name Origin 
C57BL/6 C57BL/6 
Jackson number: 664 
Charles River Breeding 
Laboratories, Wilmington MA, 
USA  
or 
Jackson Laboratory, Bar Harbor 
ME, USA 
CD45.1 B6.SJL-PtprcaPepcb/BoyJ 
Jackson number 002014 
DKFZ Animal Facility, 
Heidelberg, Germany 
CD90.1 B6.PL-Thy1a/CyJ 
Jackson number: 000406 
Jackson Laboratory, Bar Harbor 
ME, USA 
Foxp3-YFP B6.129(Cg)-Foxp3tm4(YFP/cre)Ayr/J 
Jackson number 016959 
A. Rudensky, Memorial Sloan 
Kettering Cancer Center, New 
York, USA 
Foxp3-GFP B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J 
Jackson number: 016958 
A. Rudensky, Memorial Sloan 
Kettering Cancer Center, New 
York, USA 
Foxp3-GFP 
CD45.1 
 DKFZ Animal Facility, 
Heidelberg, Germany 
Foxp3-GFP 
CD90.1 
 DKFZ Animal Facility, 
Heidelberg, Germany 
   
Tcf7-/- Tcf7tm1Cle, ∆VII H. Clevers, Hubrecht Institute 
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Utrecht, Netherlands 
Tcf7-/- Foxp3-YFP  DKFZ Animal Facility, 
Heidelberg, Germany 
Tcf7-/- TEa  DKFZ Animal Facility, 
Heidelberg, Germany 
TEa B6.Cg-Tg(Tcra,Tcrb)3Ayr/J 
Jackson number: 005655 
J. Marie, Cancer Research 
Center, Lyon, France 
 
6.2 Mammalian and bacterial cell lines 
 
Cell line Origin 
Phoenix-ECO 
Human kidney cells 
I. Grummt, DKFZ, Heidelberg, Germany 
DH5α 
Bacterial cells  
P. Frappart, DKFZ, Heidelberg, Germany 
 
6.3 DNA plasmids 
 
Insert Vector Origin 
Human Foxp3 MSCV Thy1.1 V. Heissmeyer, Helmholtz 
Zentrum München, 
Germany 
Ctrl (no insert) MSCV Thy1.1 V. Heissmeyer, Helmholtz 
Zentrum München, 
Germany 
pCL-ECO (contains viral 
proteins) 
Helper packaging construct for 
retroviral transduction 
V. Heissmeyer, Helmholtz 
Zentrum München, 
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Germany 
 
6.4 Antibodies, streptavidin and dyes 
 
Antigen Clone Isotype Company 
Bcl-2 BCL/10C4 Mouse IgG1 κ BioLegend 
Biotin  Streptavidin BioLegend 
CD103 2E7 Arm. Hamster IgG BioLegend 
CD11b M1/70 Rat IgG2b κ BioLegend 
CD11c N418 Arm. Hamster IgG BioLegend 
CD122 5H4 Rat IgG2a κ BioLegend 
CD19 6D5 Rat IgG2a κ BioLegend 
CD25 PC61 Rat IgG1 λ BioLegend 
CD28 37.51 Syr. Hamster IgG BioLegend 
CD304 (Nrp-1) N43-7 Rat IgG2a κ BioLegend 
CD304 (Nrp-1) N43-7 Rat IgG2a κ BioLegend 
CD357 (GITR) DTA-1 Rat IgG2b λ BioLegend 
CD357 (GITR) DTA-1 Rat IgG2b λ BioLegend 
CD39 5F2 Mouse IgG1 κ BioLegend 
CD3ε 145-2C11 Arm. Hamster IgG BioLegend 
CD4 RM4-5 Rat IgG2a κ BioLegend 
CD4 GK1.5 Rat IgG2b κ BioLegend 
CD44 IM7 Rat IgG2b κ BioLegend 
CD49b DX5 Rat IgMκ BioLegend 
CD5 53-7.3 Rat IgG2a κ BioLegend 
CD61 2C9.G2 (HMb3-1) Arm. Hamster IgG BioLegend 
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CD69 H1.2F3 Arm. Hamster IgG BioLegend 
CD86 GL-1 Rat IgG2a κ BioLegend 
CD86 GL-1 Rat IgG2a κ BioLegend 
CD8a 53-6.7 Rat IgG2a κ BioLegend 
CD90.1 OX-7 Mouse IgG1 κ BioLegend 
CTLA-4 UC10-4B9 Arm. Hamster IgG BioLegend 
Fixable Viability Dye   eBioscience 
FoxP3 FJK-16s Rat IgG2a κ eBioscience 
GARP YGIC86 Rat IgG2a κ BioLegend 
Hamster-IgG Lot#06008 Goat IgG MP Biomedicals 
Helios 22F6 Arm. Hamster IgG BioLegend 
I-E (MHC II) 14-4-4S Mouse IgG2a κ BioLegend 
IL-17A TC11-18H10.1 Rat IgG1 κ BioLegend 
K14 polyclonal Rabbit IgG Covance 
Ki-67 B56 Mouse IgG1 κ Cell Signaling 
KLRG1 2F1 Syr. Hamster IgG2κ BioLegend 
LEF1 C12A5 Rabbit IgG Cell signaling 
mCD1d   tetramer PBS-57 NIH tetramer core 
facility 
Rabbit-IgG  Goat IgG Cell signaling 
Rabbit-IgG  Goat IgG Jackson 
ImmunoResearch 
TCF1 C63D9 Rabbit IgG Cell signaling 
TCR Vα2 B20.1 Rat IgG2a, λ BioLegend 
TCR Vβ6 RR4-7 Rat IgG2b, λ BioLegend 
TCR γ/δ GL3 Hamster IgG BioLegend 
TCR-β-chain H57-597 Arm. Hamster IgG BioLegend 
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6.5 Cytokines 
 
Cytokine Company 
IL-6 recombinant murine tebu-bio 
IL-15 recombinant murine  PeproTech 
Proleukin S (recombinant human IL-2) Novartis Pharma 
TGFβ1 recombinant human tebu-bio 
 
6.6 Enzymes 
 
Enzyme Company 
Super Script II Reverse Transcriptase Life Technologies 
Taq DNA Polymerase 
(Vektor: pTTQ18) 
Amersham Biosciences 
and 
K. Lobbes, DKFZ, Heidelberg, Germany 
Trypsin-EDTA Sigma-Aldrich 
 
 
6.7 Quantitative real-time PCR primer 
 
Gene name Forward primer sequence 5’-3’ Reverse primer sequence 5’-3’ 
Hprt CTTTGCTGACCTGCTGGATT TATGTCCCCCGTTGACTGAT 
Tcf7 CGAGAAGAGCAGGCCAAGTA CCTGTGGTGGATTCTTGATG 
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6.8 PCR primer for tail typing 
 
Gene name Forward primer sequence 5’-3’ Reverse primer sequence 5’-3’ 
YFP-Cre AGGATGTGAGGGACTACCTCCTG
TA 
TCCTTCACTCTGATTCTGGCAATT
T 
DTR GGTGGTGCTGAAGCTCTTTC CCCATGACACCTCTCTCCAT 
TEa CCAGAAAGGGTGAAGTTGAGAGC
TG 
AAAGAAACTCGAGCCAAACTATG
AACAAGTGG 
Tcf7 ACCTTTTCACCCCAGCTTTC 
and 
CTAAAGCGCATGCTCCAGACT 
ATTCCCCTTCCTGTGTTGAG 
IEк CTAGCCCACTGCAAAAGGAG CCCAGGAATGAAACTGGTTG 
 
 
 
 
 
 
6.9 Reagents and Kits 
 
Reagent/Kit Company 
2-Log DNA ladder New England Biolabs 
4',6-Di-Amidino-2-Phenylindole (DAPI) Sigma-Aldrich 
6-Bromoindirubin-3’-oxime (BIO) Biomol 
ACK lysis buffer Lonza 
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Ampicillin Carl Roth 
Anti-Biotin Micro-Beads Miltenyi Biotec  
Brefeldin A Biozol Diagnostica 
CHIR99021 Biomol 
Chloroform  Carl Roth 
Deoxyribonucleotide Triphosphates (dNTPs) Life Technologies  
DMEM, High Glucose, with or without Phenol 
Red  
Life Technologies  
DMSO Genaxxon Bioscience 
Dulbecco's Phosphate Buffered Saline (PBS) Sigma-Aldrich 
Dynabeads mouse T-activator CD3/CD28 Life Technologies  
Ethidium bromide 1 % solution Sigma-Aldrich 
Fetal Calf Serum (FCS) (Cat. No. A15-101, 
Lot No. A10109-2802) 
PAA Laboratories  
  
Foxp3 / Transcription Factor Staining Buffer 
Set 
eBioscience 
Gelatine Solution Pan Biotech 
GlycoBlue Life Technologies  
HEPES Solution PAA Laboratories  
Ionomycin Biomol 
Mounting medium aqueous  Dako 
Nuclease free sterile water  Biomol 
Oligo(dT) primers Life Technologies 
OneComp compensation beads eBioscience 
Phorbol 12-Myristate 13-Acetate (PMA) Biomol 
Polybrene (hexadimethrine bromide) Sigma-Aldrich 
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Purelink Hipure Plasmid Midiprep Kit Life Technologies 
Purelink Quick Plasmid Miniprep Kit Life Technologies 
Retronectin Axxora 
RNAse Inhibitor Genaxxon Bioscience 
Sodium Pyruvate Solution PAA Laboratories  
Sybr Green Power Master Mix Life Technologies  
Thioglycollate Broth Sigma-Aldrich  
TRIzol Life Technologies  
Trypan Blue Biochrom 
Tween-20 MP Biomedicals 
 
 
 
6.10 Plasticware and consumables 
 
Product Company 
96-well reaction plate MicroAmp Life Technologies 
Cell culture plates flat bottom 6, 24, 96 well  PAA 
Cell culture plates round bottom 96 well PAA 
Cell strainer 40µm BD Falcon 
Conical tubes 15 ml Nerbe Plus 
Conical tubes 50 ml Greiner GBO 
Cryo tubes 1 ml  Greiner GBO 
Nitex nylon filter  SEFAR 
Penicillin-Streptomycin solution  Sigma-Aldrich 
Pipette filter tips 1-200, 100-1000 µl StarLab 
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Pipette tips 0.1-10, 1-200, 100-1000 µl StarLab 
Reaction tubes 1.5 ml Steinbrenner Laborsysteme 
Reaction tube safe-lock Eppendorf 
Round bottom 5ml tubes BD Falcon 
Round bottom 5ml tubes with lid BD Falcon 
Serological pipettes 5, 10, 25 ml Corning 
Syringe Luer-Lok 3 ml BD 
Tissue culture flask 75cm2 Greiner 
 
 
 
 
6.11 Buffers and solutions 
 
Buffer/Solution Composition 
ACK Lysis Buffer 
PBS, 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
Na2-EDTA 
stored at RT, pH 7.3, sterile filtrated  
Complete Medium 
DMEM, 10% (v/v) FCS, 10 mM HEPES,100 
U/ml Penicillin, 100 µg/ml Streptomycin, 1 
mM Pyruvate 
stored at 4°C 
FACS buffer 
PBS, 0.1% (w/v) NaN3, 1% (v/v) FCS 
stored at 4°C, pH 7.4 
LB-Medium 
Water, 0.5% (w/v) yeast extract, 1.0% (w/v) 
tryptone, 0.5% (w/v) NaCl  
stored at 4°C, pH 7.0, autoclaved  
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Loading dye (6x) 
0.2% (w/v) bromphenol blue, 
0.2% (w/v) xylene cyanol, 
60% (v/v) glycerol, 60 mM EDTA 
stored at 4°C 
Magnesium Chloride Solution 
Water, 50 mM MgCl2 
stored at 4°C, autoclaved  
PBS 
Water, 0.27 mM KCl, 13.7 mM NaCl, 10 mM 
Na2HPO4, 0.2 mM KH2PO4
stored at RT, pH 7.4, autoclaved 
  
PBST 
PBS, 0.1% (v/v) Tween 20, 5% (v/v) FCS 
and 1% (w/v) BSA 
PCR buffer (10x) 
Water, 500 mM KCl, 200 mM Tris-HCl (pH 
8.8) 
stored at 4°C 
HBS (2x) 
Water, 50 mM HEPES (pH 7.05), 
10 mM KCl, 12 mM Dextrose, 280 mM NaCl, 
1.5 mM Na2HPO4 
stored at -20°C, pH 7.05, sterile filtrated 
CaCl2 Solution 
Water, 2 M CaCl2 
stored at -20°C, sterile filtrated  
 
6.12 Equipment 
 
Equipment Manufacturer 
AutoMACS Pro Separator Miltenyi Biotec  
Axio Imager.Z1 Carl Zeiss  
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Bacterial Incubators GFL and Infors 
Betain Sigma Aldrich 
Cell Culture Hood Safe 2020 Thermo fisher scientific 
Cell Culture Incubator, Galaxy 170 S Eppendorf  
Centrifuge 5415 R, 5424 and 5810 R Eppendorf  
Electrophoresis system Neolab 
FACSAria I, II and III BD Biosciences 
FACSCanto II, LSR II, LSRFortessa BD Biosciences 
Freezer (-20°C, -80°C) Liebherr and Thermo Fisher Scientific 
Fridge (4°C) Liebherr 
Mastercycler Pro S Eppendorf 
Nanodrop 2000 Thermo Fisher Scientific 
Neubauer Counting Chamber Karl Hecht 
pH Meter Sartorius 
Precision Balances Sartorius and Mettler 
Thermoblock Neoblock 1 Neolab 
UV gel documentation system Herolab 
ViiA 7 Real-Time PCR System Life Technologies 
 
6.13 Software 
 
Software Company 
Adobe Illustrator Adobe System 
Adobe Photoshop Adobe System 
ApE M. Wayne Davis 
AxioVision Software Carl Zeiss 
EndNote Thomson Reuters 
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E.A.S.Y. Win32 Herolab 
FACS DIVA BD Biosciences 
FlowJo Treestar 
Microsoft Office Microsoft 
Prism GraphPad 
ViiA 7 Software Applied Biosystems 
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7 Results 
 
7.1 Differential quantitative mass spectrometry of the Treg cell 
proteome 
 
Gene expression profiles of Treg cells from different tissues, subphenotypes and 
under various conditions have been studied in the past (Feuerer et al., 2010; Feuerer 
et al., 2009; Heng and Painter, 2008; Hill et al., 2007). Those revealed important 
information about differences on the mRNA level, however precise knowledge of the 
complete Treg proteome and its correlation with mRNA expression is currently 
unavailable. We decided to use a mass spectrometry (MS) based quantitative 
differential approach to compare the proteomes of murine Tconv and Treg cells. Both 
Tconv and Treg cells are part of the T cell lineage, but their function and attributes are 
quite distinct from one another. Comparison of these two groups therefore results in a 
data set that highlights the differences between their proteomes. 
To enrich for murine Treg and Tconv cells from LNs and spleens, we performed 
fluorescence-activated cell sorting (FACS). Tconv cells were identified by the 
expression of the surface markers CD4 and the absence of CD25. Treg cells were 
distinguished from Tconv cells through the high surface expression of the IL-2 receptor 
CD25 (Figure 3A, left panel). After the purification, quality was checked by flow 
cytometric reacquisition of the sorted populations and by post-sort staining for 
FOXP3. Post sort reacquisition control showed that the reacquired populations lay 
almost exclusively within their sort gates (Figure 3A, middle panel). Since activated 
Tconv cells also show elevated surface expression of CD25 we stained for the major 
Treg cell transcription factor FOXP3. FACS enriched Tconv cells were almost 
completely negative for FOXP3 and more than 90 percent of the enriched Treg cells 
were positive for FOXP3 expression (Figure 3A, right panel). Hence, both methods 
confirmed that the FACS enrichment resulted in highly pure Tconv and Treg cell 
populations. 
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Figure 3: FACS purification and Proteomics work flow. (A) Sort gates for Treg (R2; CD4+CD25high) 
and Tconv (R1; CD4+CD25-) cells. Post sort control of R1 and R2 cell populations and post sort FOXP3 
staining. (B) Differential Quantitative Proteomics work flow. 
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After FACS purification, proteins from Treg and Tconv cells were extracted, digested 
and differentially labeled with stable isotopes (Boersema et al., 2009) (Figure 3B). 
Peptide fractions were then analyzed by high-resolution nano liquid chromatography-
tandem MS (LC-MS/MS) and relative protein abundance was determined based on 
relative MS signal intensities (Figure 3B). All MS experiments were performed in 
collaboration with Dr. Jeroen Krijgsveld and Dr. Jenny Hansson from the EMBL in 
Heidelberg. 
Analysis of the four MS replicate identified in total of 5225 proteins, 4859 proteins 
were detected in at least two and 3756 were detected in all four replicates (Figure 
4A). Various protein classes and cell compartments, from the nucleus to the cell 
surface were covered by the identified proteins (Figure 4B). 
Comparison of the differentially expressed proteins identified 164 proteins which 
were significantly (p < 0.05) differentially expressed between Treg cells and Tconv cells. 
Among these, we identified 51 proteins as under-represented (Appendix Table 1) and 
113 proteins as over-represented in Treg cells (Appendix Table 2). To better visualize 
differences, quantified proteins were plotted as fold change of Treg versus Tconv 
against p-value (Figure 5). As expected, classic Treg cell markers like FOXP3, IL-2Rβ, 
GITR and NRP1 were detected as highly over-represented in Treg cells compared to 
Tconv cells. SATB1 and PDE3b were both previously described as directly repressed 
by FOXP3 (Beyer et al., 2011; Gavin et al., 2007) and were here detected as under-
represented in Treg cells, further confirming our results. 
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Figure 4: MS replicates and protein classes. (A) Venn diagram of the quantified proteins in four 
replicates. (B) Pie chart of protein classes among the identified proteins. 
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Figure 5: MS data volcano plot. Proteins were extracted from FACS-purified Treg and Tconv cells and 
peptides were analyzed by LC-ESI-MS/MS (n=4). 4859 proteins were identified in at least 2 of 4 
replicates and were plotted as average Treg/Tconv fold change vs. p-value. Selected significantly over- 
or under-represented proteins are depicted in red or orange, respectively. 
 
For further validation of the acquired MS data, we assembled a panel of surface 
markers that were detected as differentially expressed by MS and performed flow 
cytometry to compare expression on Treg versus Tconv cells. Representative 
histograms, and quantification, are shown (Figure 6A and 6B). All obtained flow 
cytometric data confirmed the differences in expression detected by the MS. In 
addition, comparison of fold changes between Treg and Tconv cells, detected by MS 
and flow cytometry showed high correlation (R2 = 0.8017, P < 0.0001) (Figure 6C). 
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Figure 6: MS confirmation by flow cytometry. (A) Flow cytometric analysis of surface molecule 
expression on LN Treg and Tconv cells identified as differentially regulated by MS. Representative 
histograms show surface molecule expression. (B) Quantification of geometric means from 6A (n=3). 
Data points represent individual animals. Mean + SD is shown. (C) Correlation of Treg/Tconv cell protein 
fold changes detected by MS and flow cytometry. 
* P < 0.05, ** P < 0.01, *** P < 0.001 (unpaired t test). 
 
Gene expression data of Treg and Tconv cells was previously published (Feuerer et al., 
2010; Hill et al., 2007) and gives us the opportunity to correlate mRNA and protein 
expression data. To learn more about possible post transcriptional gene regulation 
we mapped the protein data onto the mRNA expression data set. Comparison of the 
significantly over- or under-represented proteins to gene expression data showed an 
overall strong correlation (p<0.0001) (Figure 7A). In the same manner, we next 
correlated significantly over- and under-represented genes to the protein data and 
likewise detected a good correlation (p<0.0001) (Figure 7B), indicating that in most 
cases protein expression follows mRNA expression. 
 
 
 
Figure 7: Correlation between mRNA and protein expression data sets. (A-B) Proteins from 
FACS-purified Treg and Tconv cells. Peptides were analyzed by LC-ESI-MS/MS (n=4). Over- or under-
represented targets are depicted in red or orange, respectively. P-values were calculated using the 
chi-square test. (A) Significantly differentially expressed proteins are highlighted onto gene expression 
data set from LN. (B) Significantly differentially expressed mRNA highlighted onto proteomics data.  
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To further analyze the similarities and difference between the protein and the gene 
expression data, we decided to directly compare fold changes detected by the two 
methods. To this end, we first selected significantly over- or under-represented 
proteins and then correlated the fold changes detected on the protein level to the 
ones detected on the mRNA level (Figure 8A, top and bottom). Next, fold change to 
fold change comparison was repeated in the same manner but this time significantly 
over- or under-represented mRNA was selected (Figure 8B, top and bottom).  
 
 
 
 
Figure 8: MS replicates and protein classes. (A-B) Protein from FACS-purified Treg and Tconv cells. 
Peptides were analyzed by LC-ESI-MS/MS (n=4). Correlation of gene expression (mRNA) and 
proteomics data. Comparison of mRNA and protein fold changes. (A) Selected by significantly 
changed protein. (B) Selected by significantly changed mRNA. Selected over- or under-represented 
targets are depicted in red or blue, respectively. 
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Overall, comparisons of significantly differentially expressed proteins and mRNAs 
showed a reasonably good correlation for most of the candidates. However, we were 
also able to identify targets with differential expression selectively at the mRNA or 
protein level. For example SLC4A1 and DNM2 were both detected as strongly under-
represented in Treg cells on the protein level yet this change was not detected on the 
mRNA level, pointing towards possible post transcriptional regulation. 
Based on their function and location, we subdivided the 164 differentially expressed 
proteins. Among the proteins associated with the plasma membrane or the cell 
surface, we identified already known but also unappreciated candidates, which might 
be interesting for antibody-mediated targeting of Treg cells. For example, P2RX7, 
SLC2A3, SLAMF1, ITGA6 or CLEC2D might be attractive Treg cell surface targets 
(Figure 9, left panel).  
 
 
 
Figure 9: MS replicates and protein classes. Proteins from FACS-purified Treg and Tconv cells. 
Peptides were analyzed by LC-ESI-MS/MS (n=4). Protein expression heat map of groups: CD-listed 
and plasma membrane, kinases and transcription factors of significantly differentially expressed 
proteins identified in 2 or more replicates. Not available (NA). 
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The kinases CKB and NME4, for which protein levels were significantly under-
represented in Treg cells, were previously not detected by analysis of gene expression 
profiles (Figure 9, upper right). The transcription factors GATA3, REL, NFKB2, 
STAT5A, NFKB1, STAT5B and of course FOXP3 were detected as over-represented 
in Treg cells. IKZF1, SATB1 and TCF7 were detected as under-represented in Treg 
cells by our MS analysis (Figure 9, lower right). 
Thus, we used quantitative mass spectrometry to delineate the proteome of Treg cells 
in comparison to the Tconv cell proteome and, thereby, identified 164 differentially 
regulated proteins. While in most cases protein follows mRNA, comparative analysis 
of the two data sets revealed some relevant differences between protein and mRNA 
expression and identified unappreciated differences on the protein level. 
 
7.2 Expression of the transcription factor TCF7 in Treg cells 
 
Our MS analysis identified 51 significantly under-represented proteins in Treg cells. 
We were especially interested in these under-represented proteins, since repression 
of gene expression is often essential for proper function and differentiation of cells. 
We cross-compared our set of 51 proteins with mRNA expression data from LN and 
thymus to screen for interesting candidates (Feuerer et al., 2010; Hill et al., 2007). 43 
of the proteins were mapped to the gene expression data and a gene cluster that 
was prominently under-represented in tTreg cells was identified through hierarchical 
clustering. The fact that this cluster included 3 genes that were previously described 
in the context of Treg cells (Figure 10), Pde3b, Satb1 and Itk (Beyer et al., 2011; 
Gavin et al., 2007; Gomez-Rodriguez et al., 2014), made it particularly interesting. 
The transcription factor Tcf7, which was also one of the strongest under-represented 
proteins in Treg cells (Appendix table 1), was also found within this cluster. The role of 
TCF7 during thymocyte differentiation has been well established (Verbeek et al., 
1995), but its function in the context of tTreg cell generation has not been analyzed. 
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Figure 10: mRNA expression cluster. Gene expression heat map of Treg and Tconv cells isolated from 
LN or thymus with greatest (red) and least (blue) gene expression. Genes selected from the 43 
significantly under-represented proteins (Treg compared to Tconv cells) identified by differential MS. 
Hierarchical clustering using Pearson’s correlation (row normalized). Red line marks cluster. 
 
The ImmGen consortium recently described a Tcf7-Lef1 co-regulated cluster of 
genes in developing thymocytes (Mingueneau et al., 2013). We matched our 
proteomics data to the Tcf7-Lef1 co-regulated cluster and thereby identified 19 
members in our data set (Figure 11A). Among those were TCF7 and LEF1, THEMIS, 
ITK and multiple CD3 family members. Interestingly, the whole cluster was 
significantly (p = 0.00015) under-represented in Treg cells in our proteome data set 
(Figure 11A and 11B). 
 
Pde3b (Gavin et al., Nature, 2007)
Itk (Gomez-Rodriguez et al., JEM, 2014)
Satb1 (Beyer et al., Nat Immunol, 2011)
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Figure 11: TCF7/LEF1 protein cluster. (A) Heat map of TCF7/LEF1 co-regulated cluster related 
proteins. (B) Force directed STRING network of interacting proteins from the TCF7/LEF1 cluster. 
 
Our quantitative proteomics analysis identified TCF7 as one of the significantly 
under-represented proteins in Treg cells. To confirm these findings, we performed 
intracellular flow cytometric staining for TCF7 in the thymus, LN and spleen (Figure 
12A). We included staining for the transcription factor LEF1, as it was part of the 
Tcf7-Lef1 co-regulated cluster and can partly compensate for TCF7 function 
(Okamura et al., 1998). In line with our MS data, we detected reduced TCF7 levels in 
Treg compared to Tconv cells in thymus, LN and spleen. Similarly, LEF1 expression 
was lower in Treg compared to Tconv cells from all 3 organs (Figure 12B). TCF7 and 
LEF1 staining of B cells was included as negative control. For the thymus, staining of 
DN cells was included since previous reports stated that TCF7 expression is highest 
at this developmental stage, which was confirmed by our analysis. 
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Figure 12: EndogeniousTCF7 and LEF1 expression. (A-B) Flow cytometric analysis of TCF7 and 
LEF1 expression in Treg, Tconv cells, B cells and DN cells from thymus, LN and spleen of Tcf7+/+ mice. B 
cells served as a negative control. (A) Representative histograms of intracellular TCF7 staining from 
individual animals and TCF7 geometric mean with mean and standard deviation (SD) (n=4). (B) 
Representative histograms of intracellular LEF1 staining from individual animals and LEF1 geometric 
mean with mean and SD (n=4). 
 
Through our comparative proteomics data and detailed analysis, we identified the 
transcription factor TCF7 as a promising candidate for further investigations in the 
context of tTreg cell generation. 
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7.3 TCF7 deficiency results in an increased fraction of Treg cells in 
the CD4SP and DP populations 
 
To study the role of TCF7 in tTreg cell differentiation, we made use of the Tcf7-/- 
mouse model (Verbeek et al., 1995). A short deletion was introduced into exon 7 of 
the Tcf7 gene which encodes for the DNA binding HMG-box region. As a result of the 
deletion, the thymus of Tcf7-deficient mice is greatly reduced in size and cellularity. 
Previous studies of the Tcf7-/- mouse showed that the T cell maturation is impaired 
with several developmental defects at the DN and DP stages of thymocyte 
development (Kovalovsky et al., 2009; Schilham et al., 1998; Verbeek et al., 1995). 
As a starting point for further investigations of the Tcf7-/- mouse, we first wanted to 
study the thymus in more detail through flow cytometric analysis and cell counting of 
the DN, DP, CD4SP and CD8SP populations (Figure 13A-C). 
Comparison of DN, DP CD4SP and CD8SP thymocytes from Tcf7-deficient (Tcf7-/-), 
heterozygous (Tcf7+/-) and wild-type (Tcf7+/+) littermate controls showed that the 
fractions of DN and CD8SP cells were increased while the fraction of DP cells was 
significantly decreased in Tcf7-/- compared to Tcf7+/- and Tcf7+/+ mice. The 
percentage of CD4SP cells was not changed in Tcf7-/- compared to the other two 
groups. No differences were detected between Tcf7+/- and Tcf7+/+ thymic populations 
(Figure 13A-B). As previously described, we found that the total cell numbers of DN, 
DP, CD4SP and CD8SP thymocytes were reduced in Tcf7-/- compared to the Tcf7+/- 
and Tcf7+/+ littermate controls (Figure 13C). The greatest difference in cell numbers 
was detected at the DP stage. Here we found that the difference between Tcf7+/+ and 
Tcf7-/- was 14-fold, while the detected difference at the DN stage was only about 4-
fold (Figure 13C, right panel). Between the Tcf7+/+ and the Tcf7+/- mice only minor 
differences in the cell numbers were detected. 
Morphologically a healthy thymus is organized into a central medulla and a peripheral 
cortex region. To control for thymic organization we performed immunohistological 
staining of Tcf7-/- and Tcf7+/+ thymi with keratin 14 (K14), a marker for thymic 
medullary epithelial cells. Tcf7-/- thymi showed an overall reduced size, but a 
relatively normal organization of the thymus into medullary and cortical regions 
(Figure 14A-B). 
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Figure 13: Analysis of the Tcf7+/+, Tcf7+/- and Tcf7-/- thymi (A-C) Flow cytometric analysis of thymic 
populations from Tcf7+/+, Tcf7+/- and Tcf7-/- mice. (A) Representative dot plots of thymic CD4 and CD8 
populations. (B) Quantified percentages with mean of DN, DP, CD4SP and CD8SP populations 
pregated on CD11b-CD11c-CD19- thymocytes. (C) Quantified cell counts of DN, DP, CD4SP and 
CD8SP populations from total thymus. Cell counts were performed using counting beads. Table shows 
fold change of the average cell count between Tcf7+/+ and Tcf7-/- from DN, DP, CD4SP and CD8SP 
populations. 
NS P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t-test or ordinary one-
way ANOVA). 
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Figure 14: Thymus immunofluorescence. (A-B) Immunofluorescence imaging of K14+ medullary 
epithelial cells from Tcf7+/+ and Tcf7-/- thymi. Representative data for 2 to 3 individual thymi is shown 
(A) 2.5-fold magnification and 500 µm scale bar. (B) 20-fold magnification and 50 µm scale bar. 
 
So far, studies of CD4 T cell development in the absence TCF7 focused on the 
development of CD4 T cells without discrimination between Tconv and Treg cells. We 
now aimed to characterize the development of tTreg cells more closely with the help of 
the Tcf7-/- model. Analysis of the Foxp3+ Treg cell frequency among the CD4SP 
population revealed that the fraction of Treg cells in Tcf7-/- mice was about three times 
larger than in Tcf7+/+ mice (5 versus 15 percent) (Figure 15A). However, the Treg cell 
count was not elevated due to the massive reduction of total thymocytes in the Tcf7-/- 
thymus (data not shown).  
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Figure 15: Influence of TCF7 on the FOXP3 expression at the CD4SP stage. (A-C) Flow 
cytometric analysis in CD4SP thymocytes from Tcf7+/+ and Tcf7-/- mice. Numbers show percentages of 
cells within the indicated box. (A) Representative plots of FOXP3 and CD25 expression in CD4SP 
cells and quantification with mean + SD from individual mice (n=5). (B) Representative plots of CD69+ 
(R2) and CD69- (R1) Treg cells among CD4SP cells. (C) Quantification and mean of B for individual 
mice (n=8).  
** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t-test). 
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CD69, a C-type lectin-like signaling receptor, is transiently expressed on DP 
thymocytes that undergo positive and negative selection. Expression of CD69 is lost 
at the CD4SP/CD8SP stage before emigration to the periphery (Feng et al., 2002; 
Nakayama et al., 2002). We subdivided the CD4SP population based on CD69 
expression into mature (CD69-) and more immature (CD69+) CD4SP thymocytes and 
looked at FOXP3 expression in these cells. In line with this, we observed that in 
Tcf7+/+ mice, differentiated FOXP3+ tTreg cells were mainly located within the mature 
CD69- compartment (Figure 15B, left). Interestingly, Tcf7-/- mice showed an almost 
equal distribution of FOXP3+ Treg cells between the CD69+ and CD69- compartment. 
And both populations were present at significantly higher frequencies of CD4SP cells 
compared to Tcf7+/+ mice (Figure 15B-C). 
FOXP3 expression depends on TCR/MHC interaction and FOXP3+ cells are therefore 
first detectable at the DP stage (Fontenot et al., 2005b). We looked at FOXP3 
expression in DP cells of Tcf7+/+ and Tcf7-/- mice and observed a 6 times higher 
frequency of FOXP3+ cells in the Tcf7-/- mice (Figure 16). 
 
 
 
Figure 16: Influence of TCF7 on the FOXP3 expression at the DP stage. Flow cytometric analysis 
of FOXP3 expression in DP thymocytes from Tcf7+/+ and Tcf7-/- mice. Numbers show percentages of 
cells within the indicated box. Representative plots of FOXP3 and CD25 expression in DP cells and 
quantification with mean + SD for individual mice are shown (n=5).  
*** P < 0.001 (unpaired t-test). 
 
In summary, analysis of the Tcf7-/- thymus compared to Tcf7+/- and Tcf7+/+ confirmed 
previous reports of reduced cellularity, changed frequencies of DN, DP, CD4SP and 
CD8SP cells and a normal organization into medullar and cortex regions. In addition, 
our observations demonstrate that the frequency of Treg cells in the CD4SP and DP 
stages is elevated in the absence of TCF7. 
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7.4 TCR-independent expression of FOXP3 in thymic DN cells 
 
It is currently believed that the expression of FOXP3 is induced in a TCR-dependent 
fashion at the DP or CD4SP stage of thymocyte development (Fontenot et al., 
2005b). Nevertheless, we examined the DN cells for the presence of FOXP3. 
Surprisingly, we detected that between 0.5 and 3 percent of the total DN cells from 
Tcf7-/- mice expressed FOXP3 (Figure 17A).  
 
 
 
Figure 17: FOXP3 expression at the DN cell stage in Tcf7-deficient mice. (A-B) Flow cytometric 
analysis of DN cells from Tcf7+/+ and Tcf7-/- mice. Mean + SD are shown for all quantified data. 
Numbers show percentages of cells within the indicated box. (A) Representative plots of FOXP3 
staining in DN cells and quantification for individual mice (n=8). (B) Representative plots of the 
identification of DN FOXP3+, CD3-, IC TCRβ-, and TCRγδ- cells (R2 gate) and quantification of R2 
depicted as percentage of total DN cells (n=6). TCRβ was intracellular (IC) stained. ** P < 0.01 
(unpaired t-test). 
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Given the current dogma that Foxp3 gene induction only occurs after TCR 
engagement, and that cells at the DN stage should not yet express a TCR, we 
decided to further study this unique cell population. For a closer analysis of the DN 
population we stained for CD3, TCRβ and TCRγδ (for γδ T cells), to exclude mature 
T cells that abrogated the expression of CD4 or CD8. Intracellular (IC) TCRβ staining 
was applied to detect cells that were just about to express or that had internalized 
their TCR. When we excluded all CD3+, TCRβ+ or TCRγδ+ DN cells we were left with 
a population of TCR- FOXP3+ DN cells that was present in the Tcf7-/- but not in the 
Tcf7+/+ mice (Figure 17B, R2). This population represented between 0.2 and 1.5 
percent of the total DN cells.  
The stable expression of the trans-membrane glycoprotein CD5 occurs only after the 
positive selection step and the CD5 surface expression level on thymocytes and 
mature T cells was directly correlated to the overall avidity of the MHC-TCR 
interaction strength during positive selection (Azzam et al., 1998). The CD5 
expression level can therefore be used as an indicator for previous TCR engagement 
and positive selection. We examined CD5 surface expression of FOXP3+ DN cells 
from Tcf7-/- mice and found that they, just like the classical DN cells, did not show 
CD5 expression (Figure 18). This is in contrast to the DP and CD4SP FOXP3+ or 
FOXP3- T cell populations in the thymus (Figure 18A-B).  
 
 
 
Figure 18: Expression of CD5 in FOXP3- and FOXP3+ cells from Tcf7-/- mice. (A-B) Flow 
cytometric analysis of CD5 expression in DN, DP and CD4SP cells from Tcf7-/- mice. (A) 
Representative histogram of CD5 staining on Foxp3+ DN, DP, and CD4SP cells from Tcf7-/- mice. (B) 
Quantification of CD5 geometric mean from DN, DP, and CD4SP FOXP3+ or FOXP3- populations. 
Mean is shown for quantified data. Each symbol represents an individual animal (n=3).  
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Notably, the CD5 expression of the FOXP3+ populations was in general higher than 
the surface expression of the FOXP3- populations. The obtained results indicate that 
FOXP3+ DN cells had no previous TCR engagement which distinguishes them from 
other FOXP3+ Treg cells. 
The DN population can be sub-divided into the DN1-DN4 developmental stages 
depending on the expression of the markers CD44 and CD25 (Figure 19A) (Godfrey 
et al., 1993). Staining of CD44 and CD25 was performed to further characterize the 
FOXP3+CD3-TCR- DN population. We thereby identified the FOXP3+ TCRβ- 
population (R1) as a transition state between DN1 and DN2, with high CD44 and low 
CD25 expression (Figure 19B, R1). In Tcf7-/- mice we also detected this transition 
population among the FOXP3- DN cells, while the population was barely present in 
Tcf7+/+ mice (Figure 19B, R2 and R3). 
 
 
 
Figure 19: Expression of FOXP3 at thymic DN1-4 stages. (A) Thymus gating scheme for the 
identification of DN1-4 stages, based on the expression of CD44 and CD25. (B) Flow cytometric 
analysis of DN cells from Tcf7+/+ and Tcf7-/- mice. Numbers show percentages of cells within the 
indicated box. TCRβ was intracellular (IC) stained. Representative plots for the gating of DN1-4 stages 
based on CD44 and CD25 staining of indicated populations (R1-R3). 
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Examination of the DN population in Tcf7-deficient mice indicates that TCF7 inhibits 
premature FOXP3 expression that can arise independently of TCR expression. 
 
7.5 FOXP3-expressing DN cells do not respond to TCR stimulation 
in vivo 
 
For a better functional characterization of the unique FOXP3-expressing DN cells in 
Tcf7-/- mice we induced the expression of a transgenic (TG) TCR in the Tcf7-/- mice 
and analyzed their ability to respond to antigen stimulation. The cognate antigen of 
our transgenic TCR is expressed on all thymic MHC class II positive APCs, including 
mTECs, cTECs and DCs. The generated mouse line expressed the “TEa” transgenic 
TCR with specificity for a peptide “Eα” derived from the MHC class II I-E molecule 
(Grubin et al., 1997). The Eα peptide from the MHC class II I-E molecule is presented 
by the MHC class II I-A. C57BL/6 mice express the restricting MHC (I-A) but not the 
donor MHC of the peptide (I-E). Since our Tcf7-/- mouse line was bred on a mixed 
C57BL/6-129 background and the 129 mouse strain expresses both, the restricting 
MHC and the donor MHC, the cognate antigen is present in a fraction of the mice. 
Since the transgenic TCRαβ chains are already expressed at the DN stage, we were 
able to study the influence of the antigen presence on FOXP3+ DN cells in our 
transgenic mice. We identified the mice that were positive for the donor peptide (Eα) 
either by PCR or antibody staining (Figure 20A-B). 
 
 
 
Figure 20: Identification of I-Eк antigen positive mice. (A) PCR from digested tail tissue identified 
mice with the I-Eк deletion (only 330bp fragment, Eα peptide-, left lane) and partially without the 
deletion (957bp + 330bp fragment, Eα peptide+, right lane). (B) Representative plots for the 
identification of I-Eк antigen expression in splenic CD19+ B cells by flow cytometry using anti-I-Eк 
antibody. 
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We were able to detect the two chains of the TEa-transgenic TCR, Vα2 and Vβ6, by 
flow cytometry. As expected, a significantly lower percentage of TCR-transgenic T 
cells was observed among the CD4SP cells from I-Eк antigen positive mice, 
indicating that a large part of the T cells carrying the transgenic TCR were deleted in 
antigen expressing mice (Figure 21A-B). In this respect, we did not detect differences 
between the Tcf7+/+ and Tcf7-/- mice (Figure 21A-B). 
We separated the transgenic T cells into TCRlow and TCRhigh TG populations for a 
more in-depth analysis of the CD4SP FOXP3- T cells (Figure 21A). Our analysis 
demonstrated that the TCRhigh TG fraction of the CD4SP FOXP3- cells was 
significantly reduced in the presence of the antigen (Figure 21C). For the CD4SP 
FOXP3+ population similar observations were made (Figure 21D-E). 
The data collected for the CD4SP cells demonstrated that we had established a 
robust model with strong negative selection pressure. Antigen exposure was even so 
strong that Treg cells only partially survived negative selection. We next started to 
analyze the DN compartment and, in line with our previous findings, FOXP3 
expressing DN cells were again only found in the Tcf7-/- mice (Figure 22A-B). TCR 
expression levels of TCR TG FOXP3+ DN were analyzed and we observed that 
FOXP3+ DN cells were mainly found in the TCRhigh compartment (Figure 22C-D). In 
contrast to the FOXP3+ CD4SP T cells, there was no influence of the cognate antigen 
presence on the FOXP3+ DN cells. The frequencies of TG TCR expressing FOXP3+ 
DN cells, as well as the expression levels of the TG TCR were not changed, 
indicating that there was no TCR engagement at the level of FOXP3+ DN cells 
(Figure 22C-D). 
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Figure 21: Analysis of CD4SP cells from TEa Tcf7-/- mice. (A-E) Flow cytometric analysis of CD4SP 
cells from TEa Tcf7+/+ and Tcf7-/- mice. Mean is shown for all quantified data. Numbers show 
percentages of cells within the indicated box. Ag+: cognate antigen is present. For quantified data: 
each dot represents one individual animal. Data pooled from 5 independent experiments. (A) 
Representative plots of the TG TCR expression identified by TCRVβ6 and TCRVα2 co-expression on 
CD4SP cells. TCR TG population divided into TCRhigh and TCRlow populations. (B) Quantified 
percentage of TCR TG among CD4SP cells in Tcf7+/+ and Tcf7 /- mice and in the presence or absence 
of the antigen. (C) Quantified percentage of TCRhigh TG population among CD4SP cells as depicted in 
A. (D) Representative plots of the TG TCR expression identified by TCRVβ6 and TCRVα2 co-
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expression among CD4SP FOXP3+ cells. TCR TG population divided into TCRhigh TG and TCRlow TG 
populations. (E) Quantified ratio of TCRhigh versus TCRlow TG cells from CD4SP Foxp3+ cells as 
depicted in D. 
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t test). 
 
 
 
Figure 22: Analysis of DN cells from TEa Tcf7-/- mice. (A-D) Flow cytometric analysis of DN cells 
from TEa Tcf7+/+ and Tcf7-/- mice. Mean is shown for all quantified data. Numbers show percentages of 
cells within the indicated box. Ag+: cognate antigen is present. For quantified data: each symbol 
represents one individual animal. Data pooled from 5 independent experiments. (A) Representative 
dot plot of FOXP3 expression in antigen negative, Tcf7+/+ and Tcf7-/- DN cells among on TCR TG cells. 
(B) Representative plots of the TG TCR expression identified by TCRVβ6 and TCRVα2 co-expression 
among DN FOXP3+ cells. TCR TG population divided into TCRhigh TG and TCRlow TG populations. (C) 
Quantified percentage of FOXP3+ cells among TCR TG DN cells. (D) Quantified percentage of 
FOXP3+ cells among TCRhigh TG DN cells as depicted in B. NS P > 0.05 (unpaired t test). 
 
In summary, we generated a Tcf7-deficient TCR-transgenic mouse model in which 
the cognate antigen was present and the FOXP3+ DN cells were forced to express 
the transgenic TCR. Even under these conditions, we did not see any evidence of 
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TCR usage, further supporting the TCR-independent origin of the FOXP3+ DN cells 
and their functional immaturity. 
 
7.6 Dosage effect: reduction of TCF7 protein level results in higher 
Treg cell generation capacity 
 
Tcf7 deficiency during early T cell development was associated with several 
complications. To avoid difficulties we decided to study Treg cell differentiation in an 
environment with reduced levels of Tcf7 but otherwise normal T cell development. 
The heterozygous Tcf7+/- mice fulfilled our criteria. We first compared the TCF7 
expression levels in the thymus, LN and spleen from Tcf7+/+, Tcf7+/- and Tcf7-/- mice 
(Figure 23A). As expected, we were not able to detect expression of TCF7 in the 
Tcf7-/- littermate mice. Expression of TCF7 in B cells was examined as an additional 
negative control. Comparison of TCF7 expression between Tcf7+/- and Tcf7+/+ 
littermate mice showed a significant decrease of TCF7 levels in Tcf7+/- Treg and Tconv 
cells from spleen, LN and thymus.  
 
 
 
Figure 23: TCF7 and LEF1 expression in different thymic population from Tcf7+/+, Tcf7+/- and 
Tcf7-/- mice. Flow cytometric analysis Treg, Tconv, B cells and DN cells from thymus, LN and spleen of 
Tcf7+/+, Tcf7+/- and Tcf7-/- mice. Mean is shown for all quantified data. Each symbol represents an 
individual animal (n=4). Tcf7+/+ data was shared with Figure 12. (A) Quantified geometric mean of 
TCF7 expression. (B) Quantified geometric mean of LEF1 expression.  
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t test). 
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Since the loss of TCF7 can be partially compensated by the cognate transcription 
factor LEF1 (Okamura et al., 1998), we also examined the expression of LEF1 in 
these cells (Figure 23B). For LEF1, no expression differences were observed 
between Tcf7+/+ and Tcf7+/- littermate mice in any of the organs. In Tconv and Treg cells 
from spleen and LN of the Tcf7-/- mice, expression of LEF1 was slightly elevated 
compare to Tcf7+/+ and Tcf7+/- mice. Surprisingly, we even observed decreased LEF1 
expression in all thymic cell populations of the Tcf7-/- compared to the Tcf7+/+ and 
Tcf7+/- mice. 
The obtained results confirmed that the Tcf7+/- mouse was the ideal model to study 
the dosage effect of Tcf7 expression. 
 
Since our main point of interest was the differentiation of Treg cells in the thymus, we 
examined the Treg precursors in the thymus. The TCR-dependent early Treg precursor 
is characterized by the expression of CD4SP CD69+CD25-FOXP3-, while the late 
TCR-independent, but common-γ-chain signaling-dependent, precursor is defined by 
the expression of CD4SP CD69+CD25+FOXP3- (Lio and Hsieh, 2008; Wirnsberger et 
al., 2009). Early and late Treg precursors were FACS-purified (Figure 26) and then 
analyzed by Tcf7-specific real-time PCR. The results obtained by real-time PCR 
revealed that gene expression levels of Tcf7 in both precursor populations isolated 
from the Tcf7+/- mice were about half that of Tcf7+/+ mice (Figure 24). 
 
 
Figure 24: Tcf7 qPCR in thymic Treg cell precursors. Analysis of Tcf7 mRNA expression in FACS-
purified FOXP3- Treg precursors from CD4SP cells of Tcf7+/+, Tcf7+/- and Tcf7-/- thymi via qPCR. Data 
are presented as percentage relative to Hprt expression. 
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CD4SP CD69+CD25+FOXP3- late Treg precursor was significantly increased in the 
Tcf7 thymus (Figure 25A). 
 
 
 
Figure 25: Treg cells and Treg precursors in the Tcf7+/+ and Tcf7+/- thymus. (A-B) Flow cytometric 
analysis of Tcf7+/+ and Tcf7+/- mice. Numbers show percentages of cells within the indicated box. 
Symbols represent individual mice. (A) Representative dot plots and quantification with mean + SD of 
the CD4SP CD69+CD25+Foxp3- late Treg precursor (n=7-12). (B) Representative dot plots and 
quantification with mean + SD of CD4SP FOXP3+ Treg cells (n=5). ** P < 0.01, **** P < 0.0001 
(unpaired t test). 
 
To compare the differentiation potential of the Tcf7+/- and Tcf7+/+ late Treg precursors 
we FACS-purified the late precursors (see gating scheme, Figure 26, R4) and 
incubated them in vitro in a cytokine stimulation assay. Cells were cultured with the 
cytokines IL-2 and IL-15, but without TCR stimulus, since development into Treg cells 
is TCR-independent at this stage. After one day in culture we measured the 
expression of FOXP3 and CD25. Under these conditions precursors from both Tcf7+/- 
and Tcf7+/+ mice differentiated into CD4+ CD25+FOXP3+ Treg cells, but Tcf7+/- cells did 
at a significantly higher level (Figure 27). 
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Figure 26: FACS layout for Treg precursor purification. Representative FACS layout for a Tcf7+/+ 
Foxp3-YFP+ thymus after AutoMACS depletion of CD8+ cells. R1: CD4SP CD69-; R2: CD4SP CD69+; 
R3: CD4SP CD69-CD25-Foxp3- (CD69- control population); R4: CD4SP CD69+CD25+Foxp3- (late Treg 
precursor); R5: CD4SP CD69+CD25-Foxp3- (early Treg precursor). 
 
 
 
Figure 27: 1 day culture of the late Treg precursor. The late Treg precursor (CD4SP 
CD69+CD25+FOXP3-) was FACS-purified from Foxp3-YFP+ Tcf7+/+and Tcf7+/- mice. Cells were 
cultured for 1 day in vitro with IL-2 and IL-15 (n=3-4). Percentages of CD25+FOXP3+ cells among 
CD4+ cells were subsequently analyzed by flow cytometry. Numbers show percentages of cells within 
the indicated box. Representative dot plots and quantification with mean + SD are shown (n=3-4). 
Each symbol represents an individual mouse. ** P < 0.01 (unpaired t test). 
 
To analyze the differentiation potential of the early TCR-dependent Treg precursors, 
we tested different culture conditions using the differentiation assay (Figure 28A-B). 
The CD4SP CD69+CD25-FOXP3- early Treg precursors were FACS-purified and 
subsequently cultured for 3 days in vitro. To avoid influence from APCs, we chose a 
system that used an anti-CD3/CD28 bead-based stimulus instead. The highest 
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output in total cell number and frequency of CD4+ CD25+FOXP3+ Treg cells was 
generated with a combination of an IL-2, IL-15 and anti-CD3/CD28 stimulus (Figure 
28A-B). Under these conditions sixty to eighty percent of the cells differentiated into 
Treg cells. The combination of an IL-2 and anti-CD3/CD28 stimulus resulted in the 
lowest output of Treg cells at the end of the culture period, while culture with an IL-15 
and anti-CD3/CD28 stimulus gave an intermediate result (Figure 28B). CD69- mature 
CD4SP thymocytes served as a negative control, since they got strongly activated 
(CD25high) but had lost the ability to differentiate into Treg cells under these conditions 
(Figure 28A-B and data not shown). 
 
 
 
Figure 28: 3 day culture of the early Treg precursor under different conditions. (A-B) The early 
Treg precursor (CD4SP CD69+CD25-FOXP3-) and the CD69- control population (CD4SP CD69-CD25-
FOXP3-) were FACS-purified from Foxp3-GFP+ mice. Cells were cultured for 3 days in vitro. 
Percentages of CD25+FOXP3+ cells among CD4+ cells were subsequently analyzed by flow cytometry. 
(A) Representative dot plots for the Treg precursors and CD69- control population cultured with IL-2, 
IL15 and anti-CD3/CD28 beads. Numbers show percentages of cells within the indicated box. (B) 
Quantified percentages and cell counts of CD4+ CD25+FOXP3+ cells with mean + SD (n=3-4). Cells 
were cultured under different stimulating conditions (as depicted) with anti-CD3/CD28 beads, IL-2 
and/or IL-15. Each symbol represents an individual mouse. Cell counts were determined by flow 
cytometry. 
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with the weaker (IL-2 and anti-CD3/CD28 beads) or the full (IL-2, IL-15 and 
anti-CD3/CD28 beads) stimulus. The results demonstrated that significantly more Treg 
cells, in frequency and cell count, were generated from the Tcf7+/- precursor (Figure 
29A-B). This result was independent of the stimulus strength applied to the culture. 
The weaker stimulus generated an output of about 50 percent Treg cells, while the full 
stimulus generated about 80 percent of Treg cells from the Tcf7+/- precursor (Figure 
29A-B).  
 
 
 
Figure 29: 3 day culture of the early Treg precursor from Tcf7+/+and Tcf7+/- mice. (A-B) The early 
Treg precursor (CD4SP CD69+CD25+FOXP3-) was FACS-purified from Foxp3-YFP+ Tcf7+/+ and Tcf7+/- 
mice. Cells were cultured for 3 days in vitro. Percentages of CD25+FOXP3+ cells among CD4+ cells 
were subsequently analyzed by flow cytometry. Numbers in dot plots show percentages of cells within 
the indicated box. Mean + SD are shown for all quantified data. Each symbol represents an individual 
mouse. Cell counts were determined by flow cytometry. (A) Representative dot plots, quantified 
percentages and cell counts of CD4+ CD25+FOXP3+ cells cultured with IL-2 and anti-CD3/CD28 beads 
(n=6). (B) Representative dot plots, quantified percentages and cell counts of CD4+ CD25+FOXP3+ 
cells cultured with IL-2, IL-15 and anti-CD3/CD28 beads (n=8).  
NS P > 0.05, ** P < 0.01, *** P < 0.001 (unpaired t test). 
 
Our ex vivo analysis and in vitro culture demonstrated that decreased expression of 
TCF7 results in an enhanced Treg cell differentiation capacity. 
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7.7 Limiting Treg precursor differentiation potential 
 
The Treg lineage decision strongly depends on the strength of the TCR signal. We 
modified our in vitro differentiation system to test a range of TCR signal strengths. 
We changed our strong anti-CD3/CD28 bead-based stimulus to an anti-CD3 plate 
bound system to allow increasing anti-CD3 concentrations that mimic different TCR 
affinities. To this end, we titrated the anti-CD3 antibody from 0.1 to 2 µg/ml and 
added a fixed concentration of anti-CD28. We then compared the Treg generation 
capacity of Tcf7+/+ and Tcf7+/- early precursors (Figure 30A-B). Across all anti-CD3 
concentrations tested the Tcf7+/- precursor produced a significantly higher percentage 
of Treg cells. 
 
 
 
Figure 30: Treg precursor culture with anti-CD3 titration. (A-B) The early Treg precursor (CD4SP 
CD69+CD25-FOXP3-) was FACS-purified from Foxp3-YFP+ Tcf7+/+ and Tcf7+/- mice. The cells were 
cultured in vitro for 3 days in plates coated with 0.1, 0.25, 0.5 or 2 µg/ml of anti-CD3. IL-2, IL-15 
anti-CD28 were added to the culture. Flow cytometric analysis was performed at the end of the culture 
period. (A) Representative dot plots for anti-CD3 0.1 and 2 µg/ml are shown. Numbers show 
percentages of cells within the indicated box. (B) Quantified percentages with mean + SD of CD4+ 
FOXP3+ cells generated from Tcf7+/+ and Tcf7+/- precursors after 3 days of culture (n=4). 
Representative experiment is shown.  
** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t-test). 
 
Hence, TCR-dependent differentiation into the Treg lineage is restricted by normal 
levels of TCF7 in Treg precursors. 
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Since Wnt signaling can trigger the activation of TCF7 through β-catenin (Staal et al., 
2008), we tested, in a gain-of-function experiment, if Wnt signaling could interfere 
with the development of Treg cells from Tcf7 wild-type mice. To this end, two different 
activators of the Wnt pathway were added to our anti-CD3/CD28 bead-based Treg 
differentiation assay. The early Treg precursor was cultured in the presence of the 
Wnt signaling activators 6-bromoindirubin-3’-oxime (BIO) and CHIR99021 (Figure 
31A-B). Both Wnt activators are inhibitors of the Wnt negative regulator glycogen 
synthase kinase 3 (GSK-3). Frequencies of Treg cells generated in the presence of 
BIO or CHIR99021 at different concentrations were significantly reduced (Figure 
31A-B). 
 
 
 
Figure 31: Treg precursor culture with β-CATENIN/TCF7 activators. (A-B) The early Treg precursor 
(CD4SP CD69+CD25-FOXP3-) was FACS-purified from Foxp3-GFP+ mice. The cells were cultured in 
vitro for 3 days with IL-2, IL-15, anti-CD3/CD28 and β-CATENIN/TCF7 activators. Cells cultured with 
DMSO served as a control. Percentages of CD25+FOXP3+ cells among CD4+ cells were subsequently 
analyzed by flow cytometry. Numbers in dot plots show percentages of cells within the indicated box. 
Data points represent individual animals. Representative experiments are shown. (A) Representative 
dot plots of cells cultured with BIO 1 µM or DMSO and quantified percentages with mean + SD of 
CD4+ CD25+FOXP3+ cells cultured with BIO 1µM, BIO 2 µM or DMSO are shown (n=3). (B) 
Representative dot plots and quantified percentages with mean + SD of CD4+ CD25+FOXP3+ cells 
cultured with CHIR99021 2µM or DMSO are shown (n=4). **** P < 0.0001 (unpaired t-test). 
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For a closer look at the role of TCF7 in the development of Treg cells, we examined 
the TCF7 expression levels at the different developmental stages. TCF7 expression 
stayed roughly at the same level in DP cells as well as, early and late Treg precursors. 
In mature FOXP3+ Treg cells we saw a massive drop in TCF7 levels (Figure 32). We 
previously described that the TCF7 expression was decreased in thymic Treg 
compared to Tconv cells (Figure 12A). This analysis revealed the decrease in TCF7 
expression levels occurred after both, the early and the late Treg precursor stage and 
in coincidence with the first expression of FOXP3 in these cells.  
 
 
 
Figure 32: TCF7 expression in different thymic populations. Flow cytometric analysis of TCF7 
expression in different cell populations of the thymus from C57BL/6 wild-type mice (as indicated). 
Quantification with mean + SD of the TCF7 geometric means are plotted. Data points represent 
individual animals (n=4). 
 
Based on our findings that decrease of TCF7 expression coincided with the first 
expression of FOXP3 in thymic Treg cells, we decided to analyze if FOXP3 can 
influence the TCF7 expression level. To this end, we retrovirally over-expressed 
FOXP3 in isolated peripheral T cells in vitro (Figure 33). T cells transduced with the 
control vector construct expressed CD90.1 only. T cell transduced with the Foxp3 
vector over-expressed both CD90.1 and FOXP3. Indeed, we observed that Foxp3 
over-expressing T cells showed significantly decreased levels of TCF7, while T cells 
transduced with the control vector did not (Figure 33). These results demonstrated 
that FOXP3 induces a decrease of TCF7 on the protein level. 
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Figure 33: Relationship between FOXP3 and TCF7. Flow cytometric analysis of retroviral over 
expression of control- (CD90.1+) or FOXP3-vector (CD90.1+ and FOXP3+) in T cells 3 days after 
transduction. Left panel: Representative dot plots of the CD90.1 and TCF7 expression in transduced T 
cells analyzed. Numbers in dot plots show percentages of cells within the indicated box. Middle panel: 
histograms of TCF7 expression in CD90.1- and CD90.1+ T cells. Right panel: Quantification of the 
TCF7 geometric mean in CD90.1- and CD90.1+ cells (n=2-3). Representative data from two 
independent experiments is shown. ** P < 0.01 (unpaired t test).  
 
Forced expression of the anti-apoptotic factor B cell lymphoma 2 (BCL-2) was able to 
rescue T cells from negative selection (Strasser, 2005). TCF7 was reported to reduce 
the level of BCL-2 in post-selected DP thymocytes (Kovalovsky et al., 2009). Hence, 
we examined the expression levels of BCL-2 in the early and late Treg precursors and 
found the BCL-2 expression was significantly elevated in both precursor populations 
from the Tcf7-/- compared to the Tcf7+/+ mouse, indicating that TCF7 reduces BCL-2 
expression (Figure 34A-B). 
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Figure 34: Expression of the anti-apoptotic marker BCL-2 Treg precursors. (A-B) Intracellular 
staining for the anti-apoptotic marker BCL-2 in thymic cells from Tcf7+/+ or Tcf7-/- mice was analyzed 
using flow cytometry. (A) Representative histograms of BCL-2 expression in the early and late Treg 
precursors, including isotype, controls are shown. (B) Quantification of the BCL-2 geometric mean with 
mean value is shown. Symbols represent individual mice (n=3). 
* P < 0.05, ** P < 0.01 (unpaired t test). 
 
The overall avidity of the MHC-TCR interaction during positive selection was 
previously described to correlate with the surface expression of CD5 (Azzam et al., 
1998). CD5 surface expression levels are usually higher on Treg cells compared to 
the Tconv cells. This is presumably due to the higher affinity of their TCRs towards 
self-peptide (Figure 18). We analyzed the CD5 surface expression in the early and 
late Treg precursors and the mature tTreg cells from Tcf7-/- and Tcf7+/+ mice (Figure 
35A-B). In the Tcf7+/+ mice, we observed a progressing decrease in the frequency of 
CD5low cells from the early to the late precursor and to the mature tTreg cell, indicating 
that the CD5low cells were not selected into the Treg cell lineage during the 
developmental process. In the absence of TCF7 on the other hand, the TCR 
committed late precursor and the differentiated tTreg cells did not show a decrease of 
CD5low cells compared to the early Treg precursor (Figure 35A-B). These findings 
indicate that the pool of Tcf7-deficient tTreg cells includes a higher fraction of Treg cells 
with low TCR affinity. 
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Figure 35: CD5 surface expression of Treg precursors. CD5 surface expression on early and late 
Treg precursors and tTreg cells from Tcf7+/+ and Tcf7-/- mice. Data was analyzed via flow cytometry. (A) 
Representative histograms are shown. The gate marks cells with a CD5 surface expression intensity 
< 104. (B) Quantified percentages with mean + SD of cells with a CD5 surface expression intensity < 
104 are shown (n=3). 
 
In summary, the results obtained demonstrated that the endogenous level of TCF7 
limits the efficiency of differentiation from Treg precursors into mature Treg cells, over a 
wide range of TCR signaling strengths. In addition activation of β-catenin/TCF7 
through Wnt signaling resulted in decreased Treg precursor differentiation capacity. 
Examination of the TCF7 levels in the thymic Treg cell development showed that the 
decrease in TCF7 expression coincided with the first expression of FOXP3. In line 
with these findings we showed that the forced over expression of Foxp3 in vitro also 
led to reduced TCF7 levels. Finally, we detected elevated levels of the anti-apoptotic 
factor BCL-2 in Tcf7-/- Treg precursors and demonstrated that Tcf7-/- tTreg cells had a 
higher frequency CD5low cells. 
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7.8 TGFβ triggered iTreg cell generation is not influenced by TCF7 
deficiency. 
 
After close analysis of thymic Treg development, we aimed to characterize the 
influence of TCF7 deficiency on the T cells in the peripheral lymphoid organs in more 
detail. Our analysis of the thymus revealed that development into the Treg cell lineage 
was facilitated in the absence of TCF7. We therefore hypothesized that after 
induction with TGFβ peripheral naïve T cells from Tcf7-/- mice would turn into iTreg 
cells at a higher rate than naïve T cells from Tcf7+/+ mice. The in vitro induction of 
iTreg cells through TGFβ was previously described (Chen et al., 2003).  
To test our hypothesis, we cultured naïve T cells from Tcf7-/- and Tcf7+/+ mice with 
rising concentrations of TGFβ. Since naïve T cells from Tcf7-/- mice were difficult to 
keep alive under normal culture conditions (IL-2 20 U/ml), higher concentrations of IL-
2 were added to the culture system (IL-2 100 U/ml) which resulted in better viability of 
the Tcf7-/- cells (data not shown). Analysis of the frequencies of CD4+ CD25+FOXP3+ 
iTreg cells generated after 3 days of culture revealed no differences between the 
Tcf7-/- and Tcf7+/+ cells (Figure 36A-B). In both groups, frequencies of iTreg cells 
generated increased with rising concentrations of TGFβ added to the culture. The 
maximum iTreg cell generation capacity, with about 90 percent iTreg cell output, was 
reached at a TGFβ concentration of 5ng/ml. The experiment was repeated but the 
expected advantage of naïve T cells from Tcf7-/- mice in iTreg cell induction was not 
observed. 
The results obtained from the iTreg cell generation assays did not show an influence 
of TCF7 on the generation of these cells. 
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Figure 36: iTreg induction with TGFβ titration. (A-B) Naïve Tconv cells (CD4+ CD62L+FOXP3-) were 
FACS-purified from spleen and LNs of Foxp3-YFP+ Tcf7+/+ and Tcf7-/- mice. The cells were cultured in 
vitro for 4 days with IL-2, anti-CD3/CD28 and different concentrations of TGFβ. Flow cytometric 
analysis was performed at the end of the culture period. (A) Representative dot plots of CD25 and 
FOXP3 expression among CD4+ cells for TGFβ 1.25 and 10 ng/ml are shown. Numbers show 
percentages of cells within the indicated box. (B) Quantified percentages of CD4+ CD25+FOXP3+ iTreg 
cells generated from Tcf7+/+ and Tcf7-/- Tconv cells after 4 days of culture (n=1). Representative 
experiment is shown. 
 
7.9 TH17 induction assay produces FOXP3+IL-17+ cells under 
Tcf7-deficient conditions. 
 
The subset of IL-17 producing T helper 17 (TH17) cells is involved in the defense 
against pathogens and has a role in the induction of tissue inflammation in the 
context of autoimmune disease (Korn et al., 2009). In vitro development of TH17 cells 
from naïve T cells is induced through the combination of TGFβ and IL-6 (Bettelli et 
al., 2006). While TGFβ alone induces the generation of iTreg cells, IL-6 inhibits this 
process and instead drives the generation of the TH17 lineage. Previous reports 
showed that TCF7 mediates the repression of the IL-17 gene locus through 
epigenetic modifications and that the absence of TCF7 leads to increased TH17 
differentiation (Ma et al., 2011; Yu et al., 2011).  
We were interested in investigating the transition phase between iTreg and TH17 cell 
generation in the Tcf7-deficient environment. We therefore analyzed the in vitro 
generation of TH17 cells from naïve Tcf7+/+ or Tcf7-/- T cells in a culture system with 
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constant concentrations of TGFβ (10 ng/ml) and gradually increasing concentrations 
of IL-6. At the end of the culture period we analyzed the expression of both FOXP3 
and IL-17 to identify the generated iTreg and TH17 cells (Figure 37A-B). As expected, 
we observed a gradual decrease of (CD4+ Foxp3+IL17-) iTreg cell generation with 
increasing concentrations of the cytokine IL-6. Frequencies of iTreg cells generated 
started dropping at an IL-6 concentration of 0.3 ng/ml and the turning point was 
reached at 0.6 ng/ml. At 0.6 ng/ml of IL-6 iTreg generation dropped to about 20 
percent iTreg output and stayed at this level even with higher concentrations of IL-6. 
We did not observe any difference between Tcf7+/+ and Tcf7-/- cells in this analysis 
(Figure 37A and 37B, top panel). Simultaneously, with the drop in iTreg cell 
generation, the frequency of IL-17 producing TH17 cells (CD4+ FOXP3-IL-17+) started 
to rise. In line with previously published results, we observed a difference between 
Tcf7+/+ and Tcf7-/- cells at this point (Yu et al., 2011). The frequency of IL-17 
producing cells generated from naïve Tcf7-/- T cells increased to about 20 percent, 
while the frequency generated from naïve Tcf7+/+ T cells stayed below 5 percent 
(Figure 37A and 37B, middle panel). Quite surprisingly, we also observed 
CD4+FOXP3+IL17+ cells that occurred among Tcf7-/- cells at a frequency of up to 5 
percent and stayed below 0.5 percent in the Tcf7+/+ cells (Figure 37A and 37B, 
bottom panel). These cells could not be clearly assigned to either of the subsets.  
In summary, the results obtained from the in vitro induction of TH17 cells confirmed 
that the TH17 cell generation is enhanced by the absence of TCF7, while there is no 
effect on the generation of iTreg. In addition, we observed the enhanced generation of 
FOXP3+IL-17+ cells under these conditions. 
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Figure 37: TH17 induction assay with IL-6 titration. (A-B) Naïve Tconv cells (CD4+ CD62L+FOXP3-) 
were FACS-purified from spleen and LNs of Foxp3-YFP+ Tcf7+/+ and Tcf7-/- mice. The cells were 
cultured in vitro for 4 days with IL-2, anti-CD3/CD28, TGFβ and different concentrations of IL-6. At the 
end of the culture period cells were treated with PMA, Ionomycin and Brefeldin A before flow 
cytometric analysis was performed. (A) Representative dot plots of IL17 and FOXP3 expression 
among CD4+ for IL6 0.03, 0.3, 0.6, and 5 ng/ml are shown. Numbers show percentages of cells within 
the indicated box. (B) Quantified percentages of CD4+ IL17-FOXP3+ (top panel), CD4+ IL17+FOXP3- 
(middle panel) and CD4+ IL17+FOXP3+ (bottom panel) cells generated from Tcf7+/+ and Tcf7-/- Tconv 
cells after 4 days of culture (n=1). A representative experiment is shown. 
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7.10 Marker panel analysis of peripheral Tconv and Treg cells: TCF7 
deficiency changes expression profiles. 
 
T cells can be phenotypically characterized through the analysis of marker 
expression. To examine whether TCF7 deficiency has an influence on the T cells 
phenotype, we assembled a collection of different Treg and T cell markers to stain 
Tconv and Treg cells from pooled LN and spleen (Figure 38A-C and 39A-C). Surface 
expression of TCRβ was analyzed to control for the level TCR expression. CD44, 
CD69 and Ki67 are markers of T cell memory, activation or proliferation, respectively. 
CD39, CD103, CTLA-4, GARP, GITR, HELIOS, KLRG1 and NRP1 are discussed as 
potential Treg cell and Treg cell subset markers. This does not exclude their expression 
on Tconv cells. The co-stimulatory molecule CD86 was identified as over-represented 
on Treg cells by our MS analysis. 
 
Analysis of the marker expression in Tconv cells demonstrated that CD86, CD103 and 
NRP1 were significantly over-represented in Tcf7-/- Tconv cells compared to Tcf7+/+ 
Tconv cells (Figure 38A, 40A, 40C and 41A). On the under-represented side, CD69 
and HELIOS are significantly changed in Tcf7-/- compared to Tcf7+/+ Tconv cells 
(Figure 38B and 40B). All other analyzed markers did not show significantly altered 
regulation (Figure 38C). 
Analysis of the marker panel in Treg cells detected that the expression of CD39, 
CD44, CD86 and CD103 was significantly over-represented in Tcf7-/- compared to 
Tcf7+/+ Treg cells (Figure 39A). GARP and HELIOS were significantly under-
represented in Treg cells from Tcf7-/- (Figure 39B). No significant changes could be 
detected for the other markers tested, even though KLRG-1 showed a strong 
tendency towards over-representation in Tcf7-/- (Figure 39C). 
Regarding CD86, CD103 and HELIOS, the pattern seen in Tconv repeated for Treg 
cells. CD86, the co-stimulatory molecule for activating CD28 and inhibitory CTLA-4 
receptors, was over-represented on Treg cells from Tcf7-/- (Figure 41A) (Carreno and 
Collins, 2002). The integrin CD103 binds to E-cadherin and is highly expressed on T 
cell and APC populations at mucosal sites (Annacker et al., 2005). CD103 was also 
described as a marker for a highly potent Treg subset specialized for epithelial 
environments (Lehmann et al., 2002). Our marker panel screen detected CD103 as 
over-represented in Treg cells of Tcf7-/- (Figure 40A).  
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Figure 38: Marker panel analysis in Tconv cells. (A-C) Flow cytometric analysis of protein marker 
expression (as depicted) on CD4+ peripheral Tconv cells of pooled LNs and spleen from Tcf7+/+, Tcf7+/- 
and Tcf7-/- mice. Quantified percentages including mean values of marker expression on peripheral 
Tconv cells are shown. For CD86 and GITR the quantified geometric mean is shown instead of the 
percentage. Each symbol represents an individual mouse. (A) Protein markers significantly over-
represented in Tcf7-/- compared to Tcf7+/- or Tcf7+/+ Tconv cells. (B) Protein markers significantly under-
represented in Tcf7-/- compared to Tcf7+/- or Tcf7+/+ Tconv cells. (C) Protein markers unchanged in Tcf7-/- 
compared to Tcf7+/- or Tcf7+/+ Tconv cells. 
NS P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Ordinary one-way ANOVA). 
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Figure 39: Marker panel analysis in Treg cells. (A-C) Flow cytometric analysis of protein marker 
expression (as depicted) on CD4+ FOXP3+ peripheral Treg cells of pooled LNs and spleen from Tcf7+/+, 
Tcf7+/- and Tcf7-/- mice. Quantified percentages including mean values of marker expression on 
peripheral Treg cells are shown. For CD86 and GITR the quantified geometric mean is shown instead 
of the percentage. Each symbol represents an individual mouse. (A) Protein markers significantly 
over-represented in Tcf7-/- compared to Tcf7+/- or Tcf7+/+ Treg cells. (B) Protein markers significantly 
under-represented in Tcf7-/- compared to Tcf7+/- or Tcf7+/+ Treg cells. (C) Protein markers unchanged in 
Tcf7-/- compared to Tcf7+/- or Tcf7+/+ Treg cells. 
NS P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (Ordinary one-way ANOVA). 
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Figure 40: Expression of CD103, HELIOS and NRP1 in Tconv and Treg cells. Flow cytometric 
analysis of protein marker expression in peripheral CD4+ Tconv and CD4+ FOXP3+ Treg cells from 
Tcf7+/+, Tcf7+/- and Tcf7-/- mice. Numbers in dot plots show percentages of cells within the indicated 
box. (A) Representative dot plots of CD103 expression. (B) Representative dot plots of HELIOS 
expression. (C) Representative dot plots of NRP1 expression. 
 
HELIOS, a member of the Ikaros transcription factor family was previously described 
as a marker for thymic derived tTreg cells (Thornton et al., 2010). Our marker panel 
screen shows a significant under-representation of HELIOS in Treg cells from Tcf7-/- 
compared to Tcf7+/+ (Figure 40B). The ectoenzyme CD39, expressed on the surface 
of Treg cells, produces adenosine from extracellular nucleotides which can than bind 
to adenosine receptors on activated Tconv cells and thereby silence them (Borsellino 
et al., 2007; Deaglio et al., 2007). We detected a significantly increased frequency of 
CD39 expression in Treg cells from Tcf7-/- mice. For Tcf7-/- Treg cells we detected a 
slight but significant over-representation of CD44 compared to Tcf7+/+. CD44 is a 
transmembrane glycoprotein involved in T cell activation and memory (Dutton et al., 
1998). Interaction between E-selectin and CD44 is involved in leukocyte rolling (Yago 
et al., 2010). The leucine-rich molecule GARP is expressed on the surface of a high 
fraction of activated Treg cells and binds TGFβ in its latent form to the surface of Treg 
cells. Even though the mechanism is not completely clear, binding of latent TGFβ to 
their surface is likely a way for Treg cells to confer immune tolerance (Probst-Kepper 
and Buer, 2010). We detected a significantly reduced level of GARP+ Treg cells in 
Tcf7-/- mice compared to Tcf7+/+. KLRG1, which showed a trend towards over-
representation in Treg cells from Tcf7-/- mice is an inhibitory lectin-like receptor that is 
a marker for a small but potent Treg cell subpopulation (Beyersdorf et al., 2007).  
The frequency of CTLA-4+ cells among Tcf7-/- Treg cells showed a trend toward 
reduction but was not significantly reduced (Figure 39C and 41B). The negative 
regulator of T cell activation CTLA-4 engages with its ligands CD80 or CD86 and 
thereby modifies the signals of the TCR. CTLA-4 transcription is induced by T cell 
activation and CTLA-4 expression is hence not found on naïve T cells (Rudd et al., 
2009). CTLA-4 is also an essential molecule for Treg cell suppressive function (Wing 
et al., 2008). Closer analysis of the Foxp3+ but CTLA-4- Treg cells showed this 
population was significantly increased among Treg cells from Tcf7-/- compared to 
Tcf7+/+ (Figure 41C, R1). 
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Figure 41: Expression of CD86 and CTLA-4 in Tconv and Treg cells. Flow cytometric analysis of 
protein marker expression in peripheral CD4+ Tconv and CD4+ FOXP3+ Treg cells from Tcf7+/+, Tcf7+/- 
and Tcf7-/- mice. (A) Representative dot plots of CD25 and FOXP3 expression. Numbers in dot plots 
show percentages of cells within the indicated box. (B) Quantified percentages with mean + SD of 
FOXP3+, CD25-FOXP3+ or CD25+FOXP3+ populations as indicated in A. Each symbol represents an 
individual animal. ** P < 0.01 (unpaired t test). 
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In summary, CD86, CD103 and HELIOS showed a similar regulatory pattern in Tconv 
and Treg cells from Tcf7-/- compared to Tcf7+/+ mice, while NRP1, CD39, CD44 CD69 
GARP and CTLA-4 expression was differentially influenced in Treg and Tconv by TCF7 
deficiency. KLRG1 showed a tendency towards over-representation in Treg cells from 
Tcf7-/-. We did not detect changes for Ki67, TCRβ or GITR. 
 
7.11 Tcf7 deficiency induces elevated frequencies of CD25- FOXP3+ 
Treg cells. 
 
All murine Treg cells subsets are usually phenotypically described, and are 
distinguished from other T cells, by a high expression of the IL-2 receptor molecule 
CD25 in combination with the expression of their master transcription factor FOXP3 
(Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003). For FACS purification, 
FOXP3 staining cannot be applied and differentiation between Tconv and Treg cells has 
to rely on CD25 staining. 
We stained CD4+ T cells from thymus, LN and spleen of Tcf7+/+ Tcf7+/- and Tcf7-/- 
mice for CD25 and FOXP3 to look at Treg cells frequencies in these different organs 
(Figure 3.38A-B). We first quantified the fraction of CD4+ FOXP3+ Treg cells from all 3 
organs (Figure 42B, left panel). As we had previously detected for Foxp3+ Treg cells 
from the thymus, the frequency of CD4 FOXP3+ Treg cells was significantly elevated 
in Treg cells from Tcf7-/- compared to Tcf7+/- or Tcf7+/+ mice. In contrast to the thymus, 
where we could see a dosage effect between Tcf7+/- and Tcf7+/+, this effect was not 
detectable in the peripheral lymphoid organs. Although the Tcf7+/- plots and 
quantified data are shown, we will in the following focus on the comparison between 
Tcf7-/- and Tcf7+/+ conditions. Next, we looked at the population of CD4+ 
CD25+FOXP3+ Treg cells (Figure 42B, middle panel). We noticed that while the 
frequencies of these cells were significantly elevated in Tcf7-/- compared to the 
Tcf7+/+ mice, we could not detect a difference in the frequencies from LN and spleen. 
Last we analyzed the population of CD4+ CD25-Foxp3+ Treg cells (Figure 42B, right 
panel). Surprisingly, this population, which stayed below 2 percent under Tcf7+/+ 
conditions, rose up to about 3 times the average frequency in Tcf7-/- mice for all 3 
organs.  
In summary, in the absence of TCF7 we detected a significant increase of the CD4+ 
CD25-Foxp3+ Treg cell population from thymus, LN and spleen. 
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Figure 42: Comparative analysis of the Treg cell CD25 and FOXP3 expression in thymus LN and 
spleen. Flow cytometric analysis of CD25 and FOXP3 expression in CD4+ cells from thymus LN and 
spleen of Tcf7+/+, Tcf7+/- and Tcf7-/- mice. (A) Representative histograms CD86 expression. Numbers in 
dot plots show percentages of cells within the indicated box. (B) Representative dot plots of CTLA-4 
expression. (C) Left panel: representative dot plots of CTLA-4 and FOXP3 expression. Gate R1: 
CTLA-4- FOXP3+ cells. Right panel: quantified percentages of R1 with mean +SD. Each symbol 
represents an individual animal.  
NS P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 (unpaired t test). 
 
7.12 Tcf7 deficiency massively decreases NKT frequencies in the 
thymus and in the periphery. 
 
In addition to the effects that Tcf7 deficiency had on Tconv and Treg cells, we were also 
interested in the special T cell lineage of NKT cells which form a link between the 
innate and the adaptive immune system. NKT cells develop in the thymus and 
express a semi-invariant αβ-TCR that recognizes peptides presented by CD1d, a 
MHC class I-like molecule that has a specialized role in lipid antigen presentation. 
Besides the TCR, they also express CD4 and often NK cell markers like NK1.1. Upon 
stimulation, NKT cells can release TH1 and TH2 cytokines and chemokines (Bendelac 
et al., 2007). 
We used fluorochrome coupled CD1d tetramers complexed to PBS-57, an analogue 
to the natural lipid ligand of CD1d, to detect NKT cells in the Tcf7+/+ and Tcf7-/- mice. 
To control for unspecific binding of the PBS-57-loaded CD1d tetramer, we used an 
unloaded CD1d tetramer (Kawano et al., 1997; Klenerman et al., 2002). 
Analysis of the thymus showed a massive reduction of CD4+ CD3+ mCD1d tetramer 
binding NKT cells in the Tcf7-/- compared to the Tcf7+/+ thymus (Figure 43A-B). The 
average frequency of NKT cells in the thymus was about 5 times lower in the Tcf7-/- 
mice. While we were still able to detect low numbers of NKT cells in the thymus of 
Tcf7-/- mice, we were surprised to see that in the spleen the fraction of NKT cells 
detected was only slightly above the background detected with the unloaded CD1d 
tetramer (Figure 43C-D).  
From these results we concluded that TCF7 is of great importance for the survival of 
NKT cells. 
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Figure 43: Detection of NKT cells with mCD1d tetramers. (A-D) Flow cytometric detection of CD4+ 
NKT cells from thymus and spleen of Tcf7+/+ and Tcf7-/- mice identified by CD3 expression and mCD1d 
tetramers binding. mCD1d tetramers were loaded with PBS-57. Unloaded mCD1d tetramers were 
used as a negative control. Numbers in dot plots show percentages of cells within the indicated box. 
For all quantified data mean + SD is shown. (A and C) Representative dot plots of CD3 expression 
and mCD1d tetramer binding in CD4+ cells from (A) thymus and (C) spleen. (B and D) Quantified 
percentages of CD3+ and tetramer binding cells among CD4+ cells from (B) the thymus as depicted in 
A and (D) the spleen as depicted in C (n=7). 
NS P > 0.05, * P < 0.05, *** P < 0.001, **** P < 0.0001 (unpaired t test). 
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8 Discussion 
 
8.1 Quantitative differential mass spectrometry of the Treg cell 
proteome 
 
In this study we aimed to analyze the proteome of Treg in comparison to Tconv cells to 
validate known, and to identify new proteins that are differentially regulated in Treg 
cells. We achieved the detection of 5225 proteins and identification 164 that were 
significantly differentially regulated between Treg and Tconv cells. The MS data was 
validated on the protein level by flow cytometry and compared to existing gene 
expression data. 
The previously published Treg and Tconv cells transcriptome data (Feuerer et al., 2010; 
Hill et al., 2007) allowed us to directly compare gene expression to our MS derived 
data. Expression of most proteins mirrored mRNA expression, however, direct 
comparison of Treg/Tconv fold changes helped to recognize candidates with low to 
moderate fold changes on the mRNA level but high changes on the protein level or 
vice versa. Gene and protein expression do not always correlate, since both mRNA 
and protein expression are often modulated by post-transcriptional and 
post-translational mechanisms, e.g. RNAi or protein degradation. This kind of 
comparative analysis can be of great help to identify new targets that will not be 
recognized by only looking at the transcriptome or proteome data. 
Proteomics were in fact used in the past to analyze Treg cells. A previous study used 
differential gel-blotting to screen for proteins specifically expressed by human Treg 
cells and identify galectin-10, a glycan binding molecule, as an essential factor for the 
function of Treg cells (Kubach et al., 2007). In contrast to this study, we were not able 
to detect galectin-10 through our MS analysis. Another study performed on human 
Treg cells identified proteins that were highly expressed on the surface of human Treg 
cells (Solstad et al., 2011). Among them, they particularly emphasized CD71, CD95, 
CD147 and CD148. In line with these data, we detected an over-representation of the 
transferrin receptor CD71 and BASIGIN (CD147). CD95 and CD148 on the other 
hand were not detected by our analysis. A third data set that provided information 
about human Treg cell proteomics concentrated on differentially expressed kinases in 
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Treg cells (Konig et al., 2012). Comparison of their list of 11 differentially expressed 
kinases to our data set showed only little overlap. Since our analysis was done in 
mice and the here-described studies were done in humans, their moderate 
compliance might reflect the species differences. One other recent report used 
proteomics to investigate the murine FOXP3 interaction complex (Rudra et al., 2012). 
This work gives many new insights into the FOXP3 interaction network but does not 
provide information about proteins that are differentially expressed in Treg cells. A big 
advantage of our approach to proteomics is that we do not focus on a specific cellular 
location, but rather look at the whole cell, which gives as the chance to capture the 
full unbiased picture. 
The quality of the proteomics data set can be internally controlled for by looking at 
different aspects. One feature of good data quality is reproducibility. We detected a 
total of 5225 proteins. 4859 proteins were detected in at least two and 3756 proteins 
in all four replicates. This resulted in a solid recovery rate of 72 percent between the 
four replicates. Another way to look at the quality of proteomics data is to look at the 
expression of classical Treg cell markers. In line with our expectations, we detected 
FOXP3, IL-2Rβ, GITR and NRP1 as highly over-represented in Treg cells compared 
to Tconv cells. Additionally, SATB1 and PDE3b were detected as under-represented in 
Treg cells. Some of the classic Treg cell markers, e.g. FOXP3, were not detected in all 
4 replicates or were even not detected, e.g. CD25 or GARP. Detection of proteins 
through MS is usually limited by sample handling, protein isolation, digestion or 
efficiency of the measurement itself. In retrospect it cannot be finally determined why 
some classical proteins were not detected, but it was most likely due to the low 
number of 6x105 cells, used for the experiments, which limits recovery after protein 
extraction from the sample. The generated data represents, despite small 
shortcomings, the first full comprehensive quantitative and differential proteome of 
murine Treg and Tconv cells. 
The Treg and Tconv cell proteomics data set, together with our comparative analysis of 
the transcriptome and proteome, will be a valuable source for future research in the 
field, since they help to understand the uniqueness of Treg cells. 
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8.2 Identification and relevance of TCF7 for the development and 
function of Treg cells 
 
Based on proteomics and gene expression data comparing Treg and Tconv cells, we 
intended to find candidates to further investigate their role in the development and 
function of Treg cells. We were particularly interested in the proteins that were 
selectively under-represented in Treg cells and identified TCF7 as a promising 
transcription factor for the regulation of tTreg cell generation and function. Antibody 
staining validated the decreased Tcf7 expression in Treg compared to Tconv cells in 
different organs as predicted by our MS analysis. Different selection processes 
helped to decide on TCF7 as a candidate for further investigations. 
Matching of the significantly under-represented proteins onto gene expression data 
(Feuerer et al., 2010; Hill et al., 2007) identified a prominently under-represented 
mRNA cluster. Alongside with Tcf7 the cluster included Pde3b, Satb1 and Itk. For all 
3 genes, previous studies showed that their down regulation was essential for proper 
Treg cell function. FOXP3 actively down regulates the expression of Pde3B, which 
leads to enhanced Treg cell metabolic and proliferative fitness (Gavin et al., 2007). 
Expression of SATB1, a genome organizer, is also actively repressed by FOXP3. 
Forced expression of SATB1 in Treg cells leads to the loss of the Treg cell suppressive 
function (Beyer et al., 2011). A recent report demonstrated that functional FOXP3+ 
Treg cells develop at a higher frequency in an Itk-deficient environment (Gomez-
Rodriguez et al., 2014). Association of Tcf7 with this cluster served as an indication 
for its potential impact on Treg cells that led us to further investigations.  
The ImmGen consortium described a Tcf7-Lef1 co-regulated cluster (Mingueneau et 
al., 2013). We matched this data to our proteomics data set and found that the whole 
cluster was significantly under-represented in Treg cells. The down regulated cluster 
included, besides TCF7 and LEF1, also ITK, THEMIS, BCL11b and several CD3 
family members. THEMIS and CD3 are both involved with TCR signaling in T cells. 
During T cell development THEMIS has a role in setting the TCR signal threshold for 
positive and negative selection (Fu et al., 2013). CD3γ, CD3δ and CD3ε are part of 
the TCR complex. The zinc finger protein BCL11b was found to be essential for T cell 
lineage commitment (Ikawa et al., 2010; Li et al., 2010). The observation that several 
of the Tcf7-Lef1 co-regulated cluster members were involved in TCR signaling and 
thymic T cell differentiation further implied a role of TCF7 in these events. In the 
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future, the under–representation of these Tcf7-Lef1 cluster proteins might help to 
explain how Treg cells are differentially regulated compared to Tconv cells.  
Regarding the role of TCF7 in Treg cell function in the periphery, one recent report 
stated an association of TCF7 and FOXP3. The same study also demonstrated that 
activation of Wnt signaling, and thereby induction of TCF7, interfered with the 
suppressive activity of Treg cells (van Loosdregt et al., 2013). The role of TCF7 in 
thymic T cell development was the subject of various studies, but surprisingly none of 
those made a distinction between Tconv and Treg subsets (Kovalovsky et al., 2009; 
Staal et al., 2008; Steinke et al., 2014; Verbeek et al., 1995; Weber et al., 2011). The 
novelty of the subject made Tcf7 an even more attractive candidate for our 
investigation of thymic Treg development. 
Comparison of our proteomics data set to existing gene expression data and analysis 
of the Tcf7-Lef1 co-regulated cluster led us to further investigations regarding the role 
of TCF7 in Treg cell function and development. While a negative impact of TCF7 on 
the suppressive activity of peripheral Treg cells was recently demonstrated, virtually 
nothing is known about the role of TCF7 in thymic Treg cell differentiation.  
 
8.3 Differentiation of Treg cells in the Tcf7-deficient mouse model 
 
After the identification of TCF7 as our candidate, we intended to characterize the role 
of TCF7 in thymic Treg cell differentiation. Using the Tcf7-/- mouse model (Verbeek et 
al., 1995), we studied FOXP3+ Treg cells at the DP and CD4SP stage. In addition, we 
analyzed FOXP3 expression at the DN stage in the Tcf7-/- mice and in the 
TCR-transgenic TEa Tcf7-/- model. 
The Tcf7-/- mouse model was first described in 1995 and since then it has been used 
for numerous studies of T cell differentiation. Tcf7-deficient mice are healthy, fertile 
and show no signs of autoimmune disease. However, total cell numbers in the 
thymus are significantly reduced and defects in the development of T cells have been 
described (Steinke et al., 2014; Verbeek et al., 1995). Despite these restrictions in T 
cell development, the Tcf7-/- thymus generates functional T cells. Thus, we 
considered the Tcf7-deficient mice suitable to study the differentiation of tTreg cells.  
Our analysis of the Tcf7-/- CD4SP and DP compartments demonstrated that Tcf7 
deficiency increased the fraction of FOXP3+ Treg cells among CD4SP and DP cells. 
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This finding indicates that under wild-type conditions the presence of TCF7 inhibits 
the generation of Treg cells. One could argue that the increase in Treg cell frequencies 
is a result of the previously described defects in in the T cell compartment. Mixed BM 
chimeras of Tcf7-/- and Tcf7+/+ could clarify this issue, but unfortunately development 
of Tcf7-/- T cells is almost completely arrested at early progenitor stages if placed in 
competition to Tcf7+/+ cells. Tcf7-/- progenitors cannot compete with the Tcf7+/+ 
progenitors and BM chimeras can therefore not be used to investigate the matter 
(Weber et al., 2011). 
As stated above, we detect FOXP3+ cells at the DP stage and we assume that these 
cells are Treg precursors. However, the topic of Foxp3 expression at the DP stage is 
controversially discussed. Hsieh and colleagues describe that the major part of the 
detected FOXP3+ DP population consists of CD4SP/DP cell doublets and that real 
FOXP3+ DP cells rarely exist. They suggest that further maturation is needed for 
induction of Foxp3 expression in thymocytes (Lee and Hsieh, 2009). Since we always 
used flow cytometric height and width parameters to exclude doublets in our 
experiment we assume that the detected FOXP3+ DP cells are authentic. Another 
view on the subject is that induction of Foxp3 expression occurs after the first TCR 
engagement and can be detected starting at the DP stage of thymocyte development 
(Fontenot et al., 2005b).  
Even though we believe that Foxp3 induction usually occurs after TCR engagement, 
we performed, based on the profound impact of TCF7 on T cell lineage commitment 
(Weber et al., 2011), analysis of the DN compartment for the presence of FOXP3+ 
cells. To our surprise, we observed CD3- and TCR- FOXP3+ DN cells in the Tcf7-/- 
mice. In depth analysis of this population for CD5 expression and in the 
TCR-transgenic TEa Tcf7-/- setting indicated that the premature Foxp3 expression at 
this stage occurred independent of TCR signaling. Interestingly, we demonstrated 
that the majority of the FOXP3+ DN cells were found in a DN1-DN2 transition state. 
Previous studies described this DN1-DN2 transition state as a T cell lineage 
committed population, more abundant in neonatal mice, that is exported from the 
thymus prior to TCR rearrangement. These immature cells migrate, expand and 
colonize lymphoid organs and the gut (Lambolez et al., 2006; Peaudecerf et al., 
2011). The further fate of our DN1-DN2 FOXP3+ transition cells remains unclear. One 
possibility is that they migrate out from the thymus to other lymphoid organs to 
colonize them, but this is unlikely, since we did not detect FOXP3+ TCR- cells in the 
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periphery. Tcf7-/- mice have an incomplete block at the DN1 and DN2 stages of 
thymocyte development (Verbeek et al., 1995). It is therefore quite possible that 
these transition cells do not proceed in their development. Whether TCF7 directly 
inhibits Foxp3 expression in DN cells under wild-type conditions or if de novo 
induction of Foxp3 expression occurs due to the prolonged DN1-DN2 transition is 
currently unclear. Expression of FOXP3 in non-hematopoietic thymic epithelial cells, 
other epithelial cells and tumor cells has been suggested (Chang et al., 2005; Chen 
et al., 2008; Triulzi et al., 2013), although this issue is still controversial (Liston et al., 
2007). These previous studies suggested that Foxp3 expression can occur outside of 
the lymphoid system and thus independent of TCR signaling. Our finding that Foxp3 
expression arises independently of TCR engagement in Tcf7-/- DN thymocytes is 
astonishing and might help to reveal the mechanisms that regulate Foxp3 induction.  
Our studies of thymic Treg differentiation under Tcf7-deficient conditions revealed new 
aspects about the role of TCF7 in thymocyte development. Distinction between Tconv 
and Treg cell differentiation leads to the finding that TCF7 suppresses Treg cell 
generation at the CD4SP and DP stages. In addition, we detected premature Foxp3 
expression in Tcf7-/- DN cells that occurred in the absence of a TCR. These findings 
will contribute to a better understanding of Treg and Tconv cell differentiation in the 
thymus. 
 
8.4 The dosage effect of TCF7 and refinement of an in vitro Treg cell 
differentiation assay 
 
On the basis of our intriguing findings about the role of TCF7 in Treg cell 
differentiation, we aimed to study this process in more detail in vitro. In order to do 
so, we analyzed the differentiation of Treg precursors from Tcf7+/- and Tcf7+/+ mice in a 
differentiation assay. 
Since the T cell development under Tcf7-deficient conditions was associated with 
several defects, and due to major difficulties with the in vitro culture of Tcf7-/- Treg 
precursors, we decided to use the Tcf7+/- mice instead. T cell development in the 
heterozygous mouse was normal (Verbeek et al., 1995) but levels of TCF7 were 
significantly reduced. We detected significantly elevated fractions of early and late 
Treg precursors as well as CD4SP Treg cells in the Tcf7+/- thymus. These observations 
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were in line with the results that we obtained from the Tcf7-/- thymus and indicated 
that reduced levels of TCF7 were sufficient to enhance Treg cell generation in the 
thymus.  
To study Treg cell differentiation in vitro, we made use of a Treg precursor 
differentiation assay that had been previously introduced by Wirnsberger and 
colleagues (Wirnsberger et al., 2009). We purposefully chose an APC free system to 
avoid influence from APCs and to control the amount of TCR signal in the culture. 
The previous study used 3 day culture with a plate-bound anti-CD3 stimulus and IL-2. 
As a result they generated about 10 percent of FOXP3+ Treg cells. We introduced an 
anti-CD3/CD28 bead-based stimulation and used different combinations of the 
cytokines IL-2 and IL-15. These refinements were able to boost the efficacy of Treg 
cell commitment to up to 80 percent. As it was previously demonstrated that CD28 
co-stimulation is an important factor for the generation of Treg cells (Tai et al., 2005), it 
is likely that the addition of CD28 to the system made the biggest difference in the 
generation efficiency. Anyhow, we hereby demonstrated that TCR signaling (anti-
CD3), co-stimulation (anti-CD28) and common-γ-chain signaling (IL2 and IL-15) were 
sufficient for Treg cell differentiation from the early Treg precursor. For differentiation 
from the late Treg precursor, common-γ-chain signaling alone was sufficient and 
resulted in up to 40 percent Treg cells after 1 day of culture. Notably, we also showed 
that mature CD69- CD4SP cells had generally lost the ability to differentiate into Treg 
cells under these conditions, indicating that commitment into Treg cell lineage is 
restricted to a narrow developmental window. 
When we compared the ability of Tcf7+/- and Tcf7+/+ precursors to differentiate into 
Treg cells in our in vitro differentiation assay we observed that Tcf7+/- precursors 
committed into the Treg cell lineage at a higher frequency and generated more Treg 
cells by numbers. Since the endogenous TCF7 levels in precursors restrict Treg cell 
development under these conditions, we concluded that TCF7 has to interfere either 
with TCR signaling, co-stimulation or common-γ-chain signaling. 
Our analysis of the Tcf7+/- thymus demonstrated a dosage effect of TCF7 regarding 
the commitment to the Treg cell lineage. Reduced levels of TCF7 lead to elevated 
frequencies of CD4SP Treg cells and Treg precursors. Furthermore, decreased 
expression of TCF7 results in enhanced in vitro Treg differentiation capacity of 
precursors. Our refined Treg cell differentiation assay will serve as valuable tool for 
future investigations in the field of tTreg cell development.  
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8.5 Limiting Treg cell generation capacity 
 
Based on our findings that Treg cell differentiation capacity was limited by TCF7, we 
intended to examine this process in more detail. In order to do so, we analyzed the 
influence of TCF7 on different aspects of Treg cell development. 
To simulate different strengths of TCR stimulus we modified our Treg cell 
differentiation assay by using different concentrations of plate-bound anti-CD3, 
instead of the anti-CD3/CD28 beads. Titration of the TCR stimulus showed that 
reduction of TCF7 levels led to a Treg cell generation advantage in terms of 
frequencies and cell count over a broad range of stimuli. These results indicated that 
during the critical window of Treg cell commitment, TCF7 can function as a modulator 
of TCR stimulus and thereby restricts the access to the Treg cell lineage. Such 
modulatory effects on TCR signaling have been previously suggested for other 
factors. THEMIS has been proposed to establish the signal threshold during T cell 
positive and negative selection (Fu et al., 2013). However, this study did not look at 
Treg cell development. Another recent report suggested that expression of the 
members of the tumor-necrosis factor receptor (TNFR) family GITR, OX40 and 
TNFR2 on Treg precursors translated strong TCR signals into molecular parameters 
that promoted Treg cell differentiation (Mahmud et al., 2014). In contrast to these 
TNFR family members that facilitate the development of Treg cells, TCF7 limits Treg 
cell differentiation capacity and might be involved in shaping the Treg cell TCR 
repertoire towards higher affinity. This assumption is furthermore supported by our 
observation that Tcf7-deficient mice harbored a higher frequency of CD5low cells. We 
observed a progressive decrease in the CD5low cells from the early to the late 
precursor and to the mature tTreg cells under Tcf7+/+ conditions. Tcf7-deficient mice 
showed constant levels of CD5low cells over the course of tTreg cell generation, 
suggesting that the tTreg cell pool from the Tcf7-deficient mice contains more cells 
with a low affinity TCR. By implications, these results indicate that under wild-type 
conditions most Treg precursor with a low affinity TCR eventually do not commit to the 
Treg lineage in a process that might be mediated by TCF7. Since these important 
findings about TCR avidities under Tcf7-deficient conditions are largely based on 
CD5 surface expression, confirmation of these findings in a different model could 
strengthen our conclusion. Previous studies described the Nr4a1-GFP mouse as a 
tool to look at the TCR avidities in developing T cells, since the level of GFP 
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expressed during activation correlates to the TCR signaling strength (Moran et al., 
2011). The transcription factor Nr4a1 is part of the immediate-early response after 
TCR activation and has been implicated in negative selection (Fassett et al., 2012). 
Generation of a Tcf7-/--Nr4a1-GFP mouse would give further insight into the relation 
between TCR affinities in Treg cell development and TCF7. 
To investigate the influence of TCF7 activation on Treg cell differentiation, we 
activated the β-catenin/TCF7 pathway through Wnt signaling (Staal et al., 2008). By 
using two different Wnt activators (BIO and CHIR99021), both of them negative 
regulators of GSK3, we showed that β-catenin/TCF7 activation led to a decreased 
Treg cell differentiation potential. Previous studies demonstrated that Axin-2, a direct 
TCF7 transcriptional target (Jho et al., 2002), was increased after treatment of Treg 
cells with BIO, indicating that Wnt signaling pathway indeed got activated through 
BIO (van Loosdregt et al., 2013). The importance of the β-catenin/TCF7 activation for 
T cell development was previously demonstrated. Reconstitution of Tcf7-/- mice with a 
β-catenin interacting isoform of TCF7 restored T cell development in those mice 
(Ioannidis et al., 2001). Although Wnt signaling is one way that leads to TCF7 
activation in the thymus, other pathways are involved. Notch signaling was shown to 
trigger TCF7 in early T cells precursors (Weber et al., 2011). Another report 
described that β-catenin/TCF7 were activated down-stream of TCR signaling 
(Kovalovsky et al., 2009). It is currently unclear whether Wnt, Notch or TCR signaling 
is more critical in facilitating the events that lead to TCF7 induction and thereby to 
limitation of Treg cell differentiation. While there are so far no links between thymic 
Treg cell differentiation and TCF7 signaling, controversial reports have been published 
about the role of TCF7 signaling in peripheral Treg cells. The most recent report 
stated that TCF7/Wnt signaling interferes with proper function of Treg cells (van 
Loosdregt et al., 2013). Another report described that upon stabilization of β-catenin 
and hence activation of TCF7, they observed increased Treg cell survival (Ding et al., 
2008). Stabilization of β-catenin in the thymus inhibited the DP to SP transition and 
predisposed to thymic lymphomas (Guo et al., 2007). 
A closer look at the expression of TCF7 in Treg precursors and Treg cells 
demonstrated that the observed lower expression in Treg compared to Tconv cells 
coincided with the first expression of FOXP3. These results indicated a link between 
Foxp3 expression and down regulation of Tcf7. To test this hypothesis we retrovirally 
over-expressed Foxp3 in isolated T cells in vitro, which resulted in decreased 
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expression levels of Tcf7, suggesting an influence of FOXP3 on Tcf7 expression. 
How FOXP3 influences Tcf7 expression is still unclear. Direct interaction between 
FOXP3 and TCF7 was previously demonstrated on the protein level (van Loosdregt 
et al., 2013). Controversially, another report that performed proteomics to look at 
FOXP3 interaction partners did not detect TCF7 as one of the partners (Rudra et al., 
2012). Interestingly, the same report cross compared GATA3 and FOXP3 ChiP-
sequencing data sets and identified Tcf7 as a possibly co-regulated target (Rudra et 
al., 2012).  
For normal thymocyte development, apoptosis is a crucial process. Negative 
selection depends on apoptosis regulated by pro-and anti-apoptotic members of the 
BCL-2 family. Upon death signaling, anti-apoptotic BCL-2 is inhibited by the pro-
apoptotic BIM which triggers the mitochondrial apoptosis pathway (Strasser, 2005). 
TCF7 was previously linked to the regulation of BCL-2. Previous studies reported that 
TCF7 reduced the level of BCL-2 in DP cells after selection (Kovalovsky et al., 2009). 
Moreover, Tcf7-/- DP cells were rescued from apoptosis by transgenic expression of 
BCL-2 (Ioannidis et al., 2001). Our analysis of BCL-2 expression in early and late Treg 
precursors of Tcf7-/- mice detected higher levels of BCL-2 in both precursors. The 
increased levels of BCL-2 in the Tcf7-/- precursors might enhance their survival and 
thereby account for the higher frequency of FOXP3+ cells among the DP and CD4SP 
thymocytes. 
While we currently do not know the exact mechanism behind how TCF7 limits the 
access to the Treg cell lineage we revealed many aspects of this process. Our results 
suggest that TCF7 modulates TCR signals and thereby shapes the Treg cell TCR 
repertoire towards higher affinity clones. In addition, TCF7 seems to negatively 
influence Treg precursor expansion and survival through the reduction of BCL-2 
levels. In line with this, Treg cell differentiation capacity was reduced by the activation 
of the β-catenin/TCF7 pathway. Interestingly, forced expression of FOXP3 facilitated 
the reduction of Tcf7 levels and thus may induce a survival advantage in committed 
Treg cells. The next step for future research in this field would now be to identify the 
molecular mechanisms that underlie this process. 
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8.6 TCF7 and its effects on peripheral T cells 
 
After in detail analysis of the Treg cell generation under Tcf7-deficient conditions we 
were interested in investigating the function of Tcf7-/- peripheral Tconv and Treg cells. 
To this end, we analyzed the iTreg and TH17 cell in vitro generation potential of Tcf7-/- 
cells, characterized the marker expression patterns of Tcf7-/- Tconv and Treg cells, and 
looked at the specialized T cell lineage subset of NK T cells. 
Although the role of TCF7 in the function of peripheral Tconv and Treg cells was so far 
not subject to extensive research, there are some reports about the role of TCF7 in 
those cells. The first description of the Tcf7-deficient mouse did mainly focus on the 
thymic defects, but mentioned that T cell numbers in the LNs and spleen of Tcf7-/- 
mice were slightly reduced, however animals showed no sign of autoimmune disease 
(Verbeek et al., 1995). One previous report stated that TCF7 associated with FOXP3 
in Treg cells and that activation of β-catenin/TCF7 through Wnt signaling impaired 
FOXP3 transcriptional activity and suppressive function (van Loosdregt et al., 2013). 
In contrast, stabilization of β-catenin, the interaction partner of TCF7 in Wnt signaling, 
was described to extend the survival of Treg cells (Ding et al., 2008). For CD8+ 
effector T cells, a previous report demonstrated that TCF7 was needed for 
proliferation and transition to the central memory phenotype (Zhou et al., 2010). 
TCF7 was shown to be a critical suppressor of the IL-17 gene locus which resulted in 
increased gene expression in Tcf7-/- cells (Ma et al., 2011; Yu et al., 2011). TCF7 
was also associated with the initiation of TH2 cell fate through the induction of GATA-
3 expression and suppression of IFNγ (Yu et al., 2009). 
Since we observed such a profound impact of Tcf7 deficiency on the differentiation of 
Treg cells in thymus, we got interested in the iTreg cell generation capacity of 
peripheral T cells (Chen et al., 2003). Surprisingly, we detected no difference in the 
iTreg cell generation capacity of Tcf7-/- compared to Tcf7+/+ T cells over a broad range 
of different TGFβ concentrations. These results show that the tTreg cell generation 
advantage observed in the Tcf7-/- thymus does not apply to the periphery, indicating 
that TCF7 is not involved in the process of iTreg cell generation. iTreg and tTreg cells 
are in general quite distinct subsets, which is reflected in their different gene 
expression profiles and in the requirements needed for their generation (Feuerer et 
al., 2010; Horwitz et al., 2008).  
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In line with previous results (Ma et al., 2011; Yu et al., 2011), the induction of IL-17 
under Tcf7-/- conditions was greatly favored in our in vitro assay. Interestingly, we 
also detected the generation of an IL-17+ and FOXP3+ double-positive subset in the 
absence of TCF7 and it is possible that those cells are an artifact of the in vitro cell 
culture conditions. However, such FOXP3+IL-17+ cells have been previously 
described as suppressive peripherally derived subset of Treg cells that might play a 
role in the control of anti-microbial inflammation (Voo et al., 2009). Closer analysis of 
the phenomenon might lead to a better understanding of the Treg TH17 cell balance. 
The kinase ITK is in part involved in controlling the balance between TH17 and Treg 
cells (Gomez-Rodriguez et al., 2014). ITK is also one of the proteins found in the 
TCF7/LEF1 co-regulated cluster described previously (Mingueneau et al., 2013). This 
observation raises the possibility that ITK functions differently in the absence of 
regulation through TCF7, which might result in a disturbed balance between TH17 
and Treg cells. Therefore, it would be interesting to examine if ITK expression is 
changed under TCF7-deficient conditions.  
For a better characterization of peripheral Tconv and Treg cells under Tcf7-/- conditions, 
we compared the expression of different markers between Tcf7-/- and Tcf7+/+ cells. 
CD86 and CD103 were detected as over-represented on both Tcf7-/- Tconv and Treg 
cells, while HELIOS was detected as under-represented in both cell types. The fact 
that all 3 of them were influenced in the same way by the absence of TCF7 indicates 
that TCF7 might be directly or indirectly involved in their regulation. CD86, the ligand 
for CD28 and CTLA-4, is mainly expressed on APCs, but there are also reports that 
state the expression of functional CD86 on effector memory T cells (Carreno and 
Collins, 2002; Jeannin et al., 1999). Our MS analysis detected CD86 as over-
represented on Treg cells. However, this is not the first such finding since CD86 is 
also over-represented in Treg cells on the level of mRNA expression, as detected by 
the ImmGen consortium (Heng and Painter, 2008). Apparently, the frequency of cells 
with an effector memory phenotype among both Tconv and Treg cells is increased in 
the absence of TCF7. Interestingly, we detected an increased proportion of integrin 
CD103 expressing Tcf7-/- Tconv and Treg cells. This marker was previously described 
as expressed on cells at mucosal sites and as a marker for potent epithelial Treg cells 
(Annacker et al., 2005; Lehmann et al., 2002). Whether the greatly elevated 
frequencies of CD103+ Treg and Tconv cells are due to increased proliferation of the 
CD103+ population or to a shift of the whole T cell population towards expression of 
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CD103 is not clear. HELIOS, the transcription factor and marker of tTreg cells was 
significantly under-represented in Tcf7-/- Tconv and Treg cells (Thornton et al., 2010). 
For Treg cells this could indicate that, in the periphery of Tcf7-/- mice a smaller fraction 
of FOXP3+ Treg cells is thymus derived. It is quite possible that due to the lower 
output of cells from the thymus of those mice, peripheral T cells show a higher 
proliferation rate. Controversially, we did not detect a higher rate of proliferating Ki67+ 
cells in Tcf7-/- mice. HELIOS was only expressed by a small percentage of Tconv cells 
and a function for HELIOS in these cells is so far not known. 
In addition to the changes described above, we detected among Tconv cells from 
Tcf7-/- mice a lower fraction of activated cells, characterized by the expression of 
CD69 (Bjorndahl et al., 1988), indicating that the Tconv cells from Tcf7-deficient mice 
show a less activated phenotype.  
For Treg cells, our screen detected several changes in marker expression between 
the Tcf7-/- and Tcf7+/+ mice. The transmembrane glycoprotein CD44 is a marker of 
activation and memory in T cells (Dutton et al., 1998). Treg cells from Tcf7-deficient 
animals showed a slightly more memory-like phenotype, as determined by 
expression of CD44. The ectoenzyme CD39 is one of the mediators of Treg cell 
suppressive function (Borsellino et al., 2007; Deaglio et al., 2007). Hence, a higher 
frequency of CD39+ Treg cells in Tcf7-/- mice indicates an enhanced suppressive 
capacity of the Treg cells. In contrast, another mediator of Treg cell suppressive 
function, the surface receptor GARP, was detected on a lower frequency of Treg cells 
in the Tcf7-deficient mice (Probst-Kepper and Buer, 2010). The T cell co-stimulatory 
molecule CTLA-4 is also an essential molecule for Treg cell suppressive function 
(Rudd et al., 2009; Wing et al., 2008). Around 80 percent of Treg cells are CTLA-4+. 
We detected a higher frequency of Foxp3+ CTLA-4- Treg cells in Tcf7-/- compared to 
Tcf7+/+ mice, indicating that the mechanism of CTLA-4-mediated suppression is used 
to a lesser extend in the Treg cell population. 
Besides FOXP3, the IL-2 receptor molecule CD25 is one of the hallmarks that 
characterize murine Treg cells (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 
2003). Our analysis detected an increased CD4+ CD25-FOXP3+ Treg cell population 
from thymus, LN and spleen. For FACS purification, FOXP3 staining cannot be 
applied and differentiation between Tconv and Treg cells has to rely on CD25 staining. 
This is usually not a problem, the contamination rate of Foxp3+ cells in the Tconv 
population stays typically below 2 percent. In the case of Tcf7-/- Tconv cell sorting, a 
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contamination rate of about 5 percent would be realistic. To avoid the problem, we 
used a Foxp3-YFP mouse for sorting experiments. CD25-FOXP3+ Treg cell had 
suppressive function and showed elevated levels of CD103 expression (Nishioka et 
al., 2006). Interestingly, we also observed elevated frequencies of CD103+ Tcf7-/- Treg 
cells. Together these results indicate that the Tcf7-/- Treg cells had a more aged 
phenotype compared to the Tcf7+/+. In addition, studies in humans reported that 
increased numbers of CD25-FOXP3+ T cells were associated with the autoimmune 
disease systemic lupus erythematosus (SLE) (Horwitz, 2010). In contrast to these 
studies, it was so far not described that Tcf7-deficient mice endogenously develop 
autoimmune disease. However, one report states that Tcf7-/- mice are more prone to 
the induction of autoimmune encephalomyelitis (Yu et al., 2011). 
NKT cells, which form a link between the innate and the adaptive immune system, 
carry an αβ-TCR that recognizes lipids presented by the MHC class I-like molecule 
CD1d (Bendelac et al., 2007). Detection of NKT cells in the thymus and spleen of 
Tcf7-/- mice revealed that the numbers of NKT cells in the thymus were greatly 
reduced and NKT cells were almost absent in the spleen. These results indicated that 
TCF7 is of particular importance for the survival of NKT cells. The consequences of 
the observed NKT cell deficiency are currently unclear. In the past, deficiency of NKT 
has been linked to different autoimmune conditions, especially Diabetes type I in 
NOD mice, but so far this is still controversial and hard evidence is missing (Bendelac 
et al., 2007). However, the NKT cell deficiency might represent a link to the result that 
Tcf7-/- mice are more susceptible to the induction of autoimmune disease (Yu et al., 
2011). Also, the finding that TCF7 seems to be of great importance for the survival of 
NKT cells might in the future help to better understand their development. 
Analysis of the role of TCF7 in the periphery led to some intriguing findings. First, we 
noticed that Tcf7 deficiency does not influence iTreg cell generation in vitro and 
concluded that different mechanisms are involved in tTreg versus iTreg cell generation. 
Second, we described a FOXP3+IL-17+ cell that was generated in vitro under Tcf7-/- 
conditions only. Third, we detected changed phenotypes of Tconv and Treg cells in 
Tcf7-deficient mice. For Tconv cells we observed a less activated but more effector 
memory like phenotype. Treg cells from Tcf7-/- mice might be to a lesser extend 
thymus derived and had a more (effector) memory like phenotype. In addition, we 
observed changes in the expression of Treg cell markers needed for their suppressive 
activity. As Tcf7-/- Treg cells were described to have enhanced suppressive function 
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(van Loosdregt et al., 2013), these changes might explain how this is regulated. 
Some observed changes pointed toward a Treg cell phenotype found in aged mice. 
Last, we described the deficiency of NKT cells in Tcf7-/- mice. In conclusion, we 
described a broad spectrum of changes in cells of the T cell lineage that are all linked 
to Tcf7 deficiency. On the other hand, it cannot be excluded that the observed 
changes are caused by peripheral homeostatic expansion due to reduced T cell 
output from the thymus. 
 
8.7 Conclusions and perspectives 
 
The results of this thesis now demonstrate the involvement of the transcription factor 
TCF7 in the process of thymic Treg cell differentiation. In addition, this thesis 
increases our knowledge about the effects of TCF7 on peripheral Treg cells and other 
members of the T cell lineage. 
TCF7 was identified as a promising candidate for the regulation of Treg cell generation 
based on our differential quantitative study of the Treg and Tconv cell proteome and 
comparative analysis to gene expression data. The proteomics data set itself, with its 
5225 identified proteins, will be an important source for future studies in the field. 
Analysis demonstrated that TCF7 suppressed Treg cell generation at the CD4SP and 
DP stage. To our surprise, we observed that absence of TCF7 led to TCR 
independent premature expression of FOXP3 at the DN stage. It was further 
demonstrated that reduced levels of TCF7 elevated frequencies of Treg cells and 
precursors and led to increased differentiation potential of these precursors after TCR 
stimulation. In line with this data, activation of TCF7/β-catenin signaling had an 
inhibitory effect on the differentiation of Treg precursors. Finally it was shown that 
TCF7 reduced BCL-2 levels in Treg precursors and that expression of Foxp3 
decreased Tcf7 levels.  
Based our results we now propose a model in which TCF7 limits the generation of 
Treg cells in the thymus (Figure 44).  
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Figure 44: Model of Treg selection in the thymus. The model of Treg cell selection in the thymus 
shows the relationship between the relative avidity to self-antigen (x-axis) and the number of cells (y-
axis). Areas of Treg cell selection and negative selection are shown in blue and red, respectively. The 
red dotted line marks the area where Treg cell selection is restricted by TCF7. 
 
 
We suggest that TCF7 might restrict the access to the Treg lineage through 
modulation of the TCR signals which shapes the TCR repertoire toward higher affinity 
clones and through the reduction of BCL-2 levels in Treg precursors. Once expressed 
FOXP3 seems to inhibit Tcf7 expression. This study establishes for the first time the 
role of TCF7 in Treg cell differentiation and additional work is needed to elucidate the 
molecular mechanisms behind this process.  
 
Furthermore, we studied the influence of TCF7 on different peripheral T cell subsets. 
Analysis of iTreg generation showed that, in contrast to tTreg generation, this process 
was not influenced by TCF7. TH17 generation by Tcf7-/- T cells on the other hand was 
enhanced and also resulted in the development of IL17+Foxp3+ cells. Expression 
pattern analysis of Tconv and Treg cells showed that TCF7 deficiency changed the 
phenotype of these cells. Additionally, we noticed that the absence of TCF7 led to 
NKT cell deficiency. These results extend our knowledge about the influence of TCF7 
on peripheral T cell subsets. 
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Table 1: Proteins significantly under-represented in Treg cells. 51 significantly (p < 0.05, t-test) 
under-represented proteins in Treg compared to Tconv cells identified via quantitative differential MS. All 
proteins have an average fold change of more than 1.5 and are sorted by p-value. If protein name was 
missing gene accession number was indicated. 
 
 
Protein name or Gene 
accession number 
P-value 
Average fold change 
Treg/Tconv cells 
1 Q8C5P7 0.0043 -9.58 
2 THEMIS 0.0073 -4.12 
3 SATB1 0.0074 -2.61 
4 TCF7 0.0074 -2.62 
5 SLC4A1 0.0074 -25.38 
6 IDH2 0.0081 -2.28 
7 ACTN1 0.0107 -2.04 
8 PDK1 0.0118 -2.51 
9 CKB 0.0118 -2.81 
10 NME4 0.0118 -11.30 
11 GPD2 0.0130 -1.93 
12 RASGRP2 0.0130 -2.14 
13 PDE3B 0.0130 -22.43 
14 RASSF2 0.0135 -1.93 
15 DNM2 0.0135 -14.54 
16 CLYBL 0.0137 -2.80 
17 SPTAN1 0.0153 -1.74 
18 PADI2 0.0178 -5.29 
19 DGKA 0.0193 -1.80 
20 SPTBN1 0.0198 -1.71 
21 FLNA 0.0203 -1.68 
22 ARHGAP1 0.0204 -1.69 
23 ITPR1 0.0235 -1.84 
24 ITGB3 0.0235 -2.09 
25 CLIP1 0.0236 -2.04 
26 IKZF1 0.0239 -1.67 
27 TTLL12 0.0293 -1.85 
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28 MADD 0.0312 -1.70 
29 RANBP10 0.0312 -1.84 
30 STK4 0.0327 -1.59 
31 THY1 0.0327 -1.60 
32 ADD1 0.0327 -1.71 
33 STIM1 0.0336 -1.63 
34 DENND2D 0.0339 -2.19 
35 PRDX6 0.0343 -1.64 
36 EPB4.1 0.0343 -1.71 
37 HPCAL1 0.0358 -1.76 
38 GPR132 0.0361 -1.77 
39 EMB 0.0361 -1.88 
40 MSRA 0.0375 -1.70 
41 BPNT1 0.0378 -1.73 
42 ACSF2 0.0378 -1.80 
43 ACSS2 0.0419 -1.81 
44 ADD3 0.0437 -1.75 
45 ITK 0.0437 -2.57 
46 GRAP2 0.0445 -1.54 
47 GSN 0.0445 -2.27 
48 EHD3 0.0453 -2.23 
49 ARHGEF18 0.0473 -1.62 
50 PAOX 0.0473 -1.85 
51 FAM65B 0.0473 -1.85 
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Table 2: Proteins significantly over-represented in Treg cells. 113 significantly (p < 0.05, t-test) 
over-represented proteins in Treg compared to Tconv cells identified via quantitative differential MS. All 
proteins have an average fold change of more than 1.5 and are sorted by p-value. If protein name was 
missing gene accession number was indicated 
 
 
Protein name or Gene 
accession number 
P-value 
Average fold change 
Treg/Tconv cells 
1 NRP1 0.0016 18.04 
2 CAPG 0.0016 7.23 
3 ERGIC1 0.0035 6.33 
4 LAD1 0.0043 15.70 
5 FAM129A 0.0043 9.73 
6 GSTO1 0.0043 8.96 
7 GBP5 0.0043 4.41 
8 SH3BGRL 0.0045 3.18 
9 EPHX1 0.0073 2.78 
10 IL2RB 0.0074 10.29 
11 TNFRSF18 0.0074 9.99 
12 Q4FZC9 0.0074 2.91 
13 GALM 0.0074 2.72 
14 SAMHD1 0.0074 2.62 
15 DECR1 0.0081 3.26 
16 NT5E 0.0094 7.28 
17 PTMS 0.0094 2.36 
18 SLC2A3 0.0107 3.97 
19 SERPINB1A 0.0118 3.64 
20 SNX18 0.0118 3.46 
21 AHNAK 0.0118 3.25 
22 S100A10 0.0118 3.05 
23 H2-Q6 0.0118 2.36 
24 CTSS 0.0118 2.14 
25 LXN 0.0118 2.07 
26 GSTA4 0.0125 17.27 
27 ITGA6 0.0125 2.48 
28 IIGP1 0.0129 2.43 
29 HDGFRP3 0.0129 2.23 
30 N6AMT2 0.0130 2.41 
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31 RLTPR 0.0130 2.19 
32 REL 0.0131 2.37 
33 AHCYL2 0.0131 2.14 
34 NFKB2 0.0131 2.36 
35 ALAD 0.0131 2.20 
36 VWA5A 0.0134 2.16 
37 PLP2 0.0135 2.86 
38 ENO2 0.0137 12.93 
39 CORO2A 0.0137 11.42 
40 RCN1 0.0137 4.02 
41 PAFAH1B3 0.0137 2.48 
42 FOXP3 0.0174 9.80 
43 CD86 0.0174 3.16 
44 SAMHD1 0.0178 4.47 
45 ENO3 0.0185 7.88 
46 MYO18A 0.0185 1.88 
47 GBP7 0.0196 1.88 
48 PRKCA 0.0198 1.88 
49 FABP5 0.0203 2.87 
50 IKZF3 0.0205 2.44 
51 GPHN 0.0213 2.13 
52 GVIN1 0.0217 2.41 
53 PLEKHO2 0.0219 2.54 
54 LMNA 0.0219 1.79 
55 IGTP 0.0219 1.78 
56 HSPA4L 0.0236 2.05 
57 TREX1 0.0236 1.85 
58 TMEM173 0.0239 1.94 
59 ISG20 0.0241 2.10 
60 STAT5A 0.0241 1.97 
61 GIMAP7 0.0241 1.88 
62 NUCB2 0.0243 2.85 
63 CLEC2D 0.0247 1.94 
64 MARCKSL1 0.0281 2.54 
65 ACOT9 0.0281 1.80 
66 SHMT1 0.0291 1.63 
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67 LPXN 0.0312 2.53 
68 SCAMP2 0.0312 1.68 
69 SNX9 0.0321 4.83 
70 SLAMF1 0.0329 2.63 
71 TUBB2B 0.0329 2.38 
72 HK2 0.0336 4.61 
73 PRKRA 0.0337 2.49 
74 RAB8B 0.0337 1.71 
75 CD38 0.0339 6.68 
76 SLC25A24 0.0339 2.09 
77 REXO2 0.0343 1.88 
78 STIM2 0.0358 2.88 
79 NCF4 0.0358 2.85 
80 ADPRH 0.0361 2.00 
81 APOBEC3 0.0369 1.76 
82 SERPINB6A 0.0378 2.12 
83 CRMP1 0.0378 2.01 
84 CCL21A 0.0378 1.95 
85 CYB5A 0.0378 1.59 
86 CCS 0.0381 1.77 
87 TTC39B 0.0397 2.23 
88 MGMT 0.0397 1.97 
89 NFKB1 0.0397 1.56 
90 LRRC8C 0.0403 1.57 
91 HIP1R 0.0407 3.17 
92 P2RX7 0.0419 5.43 
93 NEK7 0.0419 1.62 
94 HRSP12 0.0426 1.63 
95 SAMSN1 0.0437 3.83 
96 STAT5B 0.0437 1.52 
97 LTA4H 0.0443 1.64 
98 GATA3 0.0445 3.75 
99 CD44 0.0445 2.52 
100 POU2F2 0.0453 7.59 
101 COMT 0.0453 1.95 
102 LIG1 0.0453 1.86 
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103 RLTPR 0.0453 2.12 
104 MYO1C 0.0456 2.81 
105 AKNA 0.0458 1.65 
106 UHRF2 0.0473 1.90 
107 ALDH18A1 0.0473 1.63 
108 ICAM1 0.0473 3.34 
109 TRP53I11 0.0480 2.60 
110 SIGIRR 0.0488 3.24 
111 CD69 0.0493 3.23 
112 LIPE 0.0498 2.09 
113 SWAP70 0.0499 7.71 
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11 Abbreviations 
 
% Percent 
α alpha 
β beta 
γ gamma 
δ delta 
°C Degree Celsius 
µg Micro gram 
µl Micro liter 
µm Micro meter 
µM Micro Molar 
A2AR adenosine receptor 2A 
ACK buffer Ammonium chloride–potassium bicarbonate cell
lysis buffer 
Ag Antigen 
APC Antigen presenting cell 
BCL-2 B cell lymphoma 2 
BIO 6-Bromoindirubin-3′-oxime 
BSA Bovine serum albumin 
Ca2+ Calcium 
cAMP Cyclic adenosine monophosphate 
CD Clusters of differentiation 
CDR Complementarity determining region 
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CHIR99021 6-(2-(4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-
imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-
nicotinonitrile 
CNS Conserved non-coding region 
CTL  Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T lymphocyte associated antigen 4 
Ctrl Control 
cTEC Cortical thymic epithelial cell 
DAPI 4’,6-Diamidino-2-Phenylindole 
DC Dendritic cell 
DMEM Dulbecco‘s Modified Eagle‘s Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DN cell CD4 and CD8 double-negative cell 
DP cell CD4 and CD8 double-positive cell 
DTR Diphteria toxin receptor 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum 
FDR False discovery rate 
FITC Fluorescein isothiocyanate 
FOXP3 Forkhead box 3 
FRET Förster resonance energy transfer 
GARP Glycoprotein-A repetitions predominant 
GFP Green fluorescent protein 
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GSK-3 Glycogen synthase kinase 3  
HEPES 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid
HMG High mobility group 
IDO Indoleamine 2, 3-dioxygenase 
IFNγ Interferon γ 
Ig Immunoglobulin 
IL Interleukin 
ILC2 Innate group 2 innate lymphoid 
IPEX Immunodysregulation polyendocrinopathy,
enteropathy X‑linked 
iTreg cell (in vitro) Induced regulatory T cell 
kD Kilo dalton 
LC-ESI-MS/MS Liquid chromatography-electrospray ionization -
tandem MS 
LEF1 Lymphoid enhancer binding factor 1 
LAG3 Lymphocyte associated gene 3 
LN Lymph node 
MHC Major histocompatibility complex 
min Minutes 
ml Milliliter 
mM Milli Molar 
mRNA Messenger RNA 
mTEC Medullary thymic epithelial cell 
MS Mass spectrometry 
MSCV Murine stem cell virus 
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NFAT Nuclear factor of activated T cells 
NLS Nuclear localization signal 
NK cell Natural killer cell 
NKT cell Natural killer T cell 
NRP1 Neuropilin 1 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
pTreg cell Peripheral induced regulatory T cell 
qPCR quantitative real-time PCR 
RNA Ribonucleic acid 
RNAi RNA interference 
rpm Rounds per minute 
RT Room temperature 
SP cell CD4 or CD8 single-positive cell 
TCF1 T cell specific transcription factor 1 
TCF7 Transcription factor 7 
Tconv cell Conventional T cell 
TCR T cell receptor 
TG Transgenic 
TGFβ Transforming growth factor β 
TH cell T helper cell 
Treg cell Regulatory T cell 
tTreg cell Thymic derived regulatory T cell 
YFP Yellow fluorescent protein 
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